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U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 
CENTERS FOR DISEASE CONTROL AND PREVENTION 
HEALTH RESOURCES AND SERVICES ADMINISTRATION 
CDC/HRSA ADVISORY COMMITTEE ON HIV, 
VIRAL HEPATITIS AND STD PREVENTION AND TREATMENT 
May 21-22, 2014 
Atlanta, Georgia 
Minutes of the Meeting 
The U.S. Department of Health and Human Services (HHS), the Centers for Disease Control 
and Prevention (CDC) National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
(NCHHSTP), and the Health Resources and Services Administration (HRSA) HIV/AIDS Bureau 
(HAB) convened a meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and 
STD Prevention and Treatment (CHAC).  The proceedings were held on May 21-22, 2014 in 
Building 8 of CDC’s Corporate Square Campus, Conference Room A/B/C, in Atlanta, Georgia. 
CHAC is chartered to advise the Secretary of HHS, Director of CDC, and Administrator of HRSA 
on objectives, strategies, policies and priorities for HIV, viral hepatitis and STD prevention and 
treatment efforts for the nation. 
Opening Session: May 21, 2014 
Jeanne Marrazzo, MD, MPH, CHAC co-Chair 
Professor of Medicine, Harborview Medical Center 
University of Washington 
Laura Cheever, MD, ScM, Acting CHAC co-Chair 
Associate Administrator, HIV/AIDS Bureau 
Health Resources and Services Administration 
CHAC Designated Federal Officer, HRSA 
Jonathan Mermin, MD, MPH 
Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
CHAC Designated Federal Officer, CDC 
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Drs. Marrazzo, Mermin and Cheever performed their duties as the CHAC co-Chair and CDC/ 
HRSA Designated Federal Officers (DFOs).  Dr. Marrazzo conducted a roll call to determine the 
CHAC voting members, ex-officio members and liaison representative who were attending the 
meeting either in person or remotely. 
Dr. Mermin announced that CHAC meetings are open to the public and all comments made 
during the proceedings are a matter of public record.  He reminded the CHAC voting members 
of their responsibility to disclose any potential individual and/or institutional conflicts of interest 
for the public record and recuse themselves from voting or participating in these matters. 
 
CONFLICT OF INTEREST DISCLOSURES 
 
CHAC Voting Member 
(Institution/Organization) Potential Conflict of Interest 
Bruce Agins, MD, MPH 
(New York State Department of Health) 
Recipient of multiple CDC and HRSA grants 
Sanjeev Arora, MD, FACP 
(University of New Mexico 
Health Sciences Center) 
Recipient of federal funding from CDC, HRSA, 
Agency for Healthcare Research and Quality 
(AHRQ), Centers for Medicare and Medicaid 
Services (CMS), and Center for Medicare and 
Medicaid Innovation; principal investigator of 
multiple clinical trials for new hepatitis C virus 
(HCV) drug development 
Virginia Caine, MD 
(Marion County, Indianapolis 
Public Health Department) 
Recipient of federal funding from CDC for STD 
activities and from HRSA for Ryan White; 
member of the National Medical Association 
Board that receives federal funding from CDC for 
HIV activities 
Guillermo Chacon 
(Latino Commission on AIDS) 
Recipient of federal funding from CDC for 
capacity-building services and from the Office of 
Minority Health for testing and research; member 
of Community Advisory Boards for Merck and 
ViiV Healthcare 
Tommy Chesbro, HR, CSE 
(Chesbro Consulting, LLC) 
Recipient of a federal contract; member of the 
National Minority AIDS Council Board of Directors 
that is a recipient of federal funding 
Angelique Croasdale, MA 
(City of Hartford, Connecticut 
Department of Health and Human Services) 
Recipient of federal funding from CDC and HRSA 
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CHAC Voting Member 
(Institution/Organization) Potential Conflict of Interest 
Carlos del Rio, MD 
(Rollins School of Public Health 
Emory University) 
Recipient of federal funding from CDC, HRSA for 
a Ryan White Clinic, and the National Institutes of 
Health (NIH) 
Marjorie Hill, PhD 
(Independent Consulting Services) 
No conflicts disclosed 
Steven Johnson, MD 
(University of Colorado School of Medicine) 
Recipient of federal funding from HRSA for Ryan 
White; consultant to Gilead Sciences and ViiV 
Healthcare 
Jennifer Kates, PhD 
(Kaiser Family Foundation) 
No conflicts disclosed 
Kali Lindsey 
(amfAR, The Foundation for 
AIDS Research) 
No conflicts disclosed 
Jeanne Marrazzo, MD, MPH 
(University of Washington) 
Recipient of federal funding from CDC for HIV, 
STD and viral hepatitis prevention education; 
recipient of pharmaceutical funding from Cepheid 
and Melinta for STD diagnostic studies and 
treatment trials 
Britt Rios-Ellis, PhD 
(California State University, Long Beach) 
Recipient of federal funding from the NIH 
National Institute on Minority Health and Health 
Disparities; pharmaceutical funding from Merck 
for Latino treatment and prevention efforts 
The voting members and ex-officio members in attendance constituted a quorum for CHAC to 
conduct its business on May 21, 2014.  The proceedings were called to order at 8:45 a.m.  Drs. 
Marrazzo, Mermin and Cheever welcomed the participants to day 1 of the 22nd CHAC meeting. 
Dr. Mermin described changes to CHAC’s membership that have occurred since the November 
2013 virtual meeting. 
• Ms. Antigone Dempsey accepted a new position at HRSA in April 2014 as the Director of 
the HAB Division of Policy and Data and could no longer serve as the CHAC co-Chair.  
The participants congratulated and extended their best wishes to Ms. Dempsey in her 
new position.  Dr. Cheever would serve as the Acting CHAC co-Chair for the current 
meeting, but efforts are underway to replace Ms. Dempsey. 
• Mr. Douglas Brooks accepted a new position as Director of the Office of National AIDS 
Policy and could no longer serve as the CHAC liaison representative for the Presidential 
Advisory Council on HIV/AIDS (PACHA).  PACHA currently is identifying a new liaison to 
replace Mr. Brooks. 
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• Dr. Paul Gaist is a Health Scientist Administrator in the NIH Office of AIDS Research.  
He has replaced Dr. William Grace as the ex-officio member for NIH. 
• The terms of four CHAC members would expire on November 30, 2014:  Dr. Perry 
Halkitis, Dr. Marjorie Hill, Dr. Jeanne Marrazzo, and Ms. Regan Hofmann.  The Federal 
Register notice that announced the upcoming vacancies in CHAC’s membership 
resulted in nominations of a large, diverse and qualified pool of candidates.  The draft 
nomination packages would be submitted to the CDC Committee Management Office for 
review at the end of May 2014 as the next step in the HHS approval and clearance 
process to appoint the new CHAC members. 
CDC/NCHHSTP Director’s Report 
Jonathan Mermin, MD, MPH 
Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
CHAC Designated Federal Officer, CDC 
Dr. Mermin covered the following topics in his Director’s report to CHAC.  At the agency level, 
the CDC FY2014 budget includes $30 million for the CDC National Center for Emerging and 
Zoonotic Infectious Diseases to establish a new Advanced Molecular Detection (AMD) Program.  
The AMD Program will target funding and efforts to five major activities. 
• Improved pathogen identification and detection 
• New diagnostics 
• Technical assistance to states to meet their bioinformatics and genomics needs 
• Enhanced laboratory information systems 
• Prediction, modeling and early recognition of infections 
CDC partnered with U.S. government agencies, other nations, international organizations, and 
public/private stakeholders to launch a “Global Health Security Agenda.”  The purpose of this 
initiative is to accelerate progress toward achieving worldwide safety and security related to 
infectious disease threats and also to promote global health security in three major areas.  First, 
the likelihood of natural, accidental or intentional outbreaks will be prevented and reduced.  
Second, threats will be detected early to save lives.  Third, multi-sectorial coordination and 
communication will be deployed internationally to ensure a rapid and effective response. 
The FY2015 President’s budget proposed a $30 million increase for the “Detect and Protect 
Against Antibiotic Resistance” initiative.  The purpose of this effort is to enhance surveillance 
and laboratory capacity at national, state and local levels to detect and characterize domestic 
antibiotic-resistant threats and protect patients from imminent danger.  If the initiative is 
approved in the FY2015 President’s budget, investments will be targeted to implementing 
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proven and evidence-based interventions (EBIs) that have the ability to reduce the emergence 
and spread of antibiotic-resistant pathogens and improve appropriate antibiotic use. 
At the National Center level, CDC’s new AMD Program awarded $917,240 to NCHHSTP to 
conduct five new AMD projects. 
1. Characterization of microbial transmission networks by combining epidemiologic and 
genetic data 
2. Advanced molecular detection of HCV outbreaks 
3. Genomic surveillance of Mycobacterium tuberculosis in New York City over the 2011-
2014 time period 
4. Whole-genome sequencing for tuberculosis (TB) outbreak detection and investigations 
5. Genomic sequencing of Neisseria gonorrhoeae to more effectively respond to the urgent 
threat of antimicrobial-resistant gonorrhea 
NCHHSTP was pleased to announce the appointment of Dr. Stephanie Zaza as the new 
Director of the Division of Adolescent and School Health.  Dr. Zaza’s distinguished career at 
CDC over the past 23 years includes her role as an Epidemic Intelligence Service Officer in 
1991 and multiple leadership positions since that time.  Dr. Zaza’s first update to CHAC was 
scheduled on the agenda. 
Sequester reductions led to the restoration of $569 million in the FY2014 CDC budget.  The 
FY2015 President’s budget requests an increase of ~$7.4 million to NCHHSTP.  If approved, 
NCHHSTP will allocate the funding increase to two major areas:  (1) $4.4 million to improve HIV 
surveillance as well as to identify and share HIV prevention best practices and (2) $3 million to 
evaluate school health programs. 
NCHHSTP implemented a new strategic planning process to identify the best approaches to 
achieve maximum impact on reducing health disparities, disease incidence, morbidity and 
mortality for HIV, viral hepatitis, STDs and TB.  NCHHSTP held meetings and retreats with staff 
at the Office of Director, division and branch levels to obtain internal input on the strategic 
planning process.  Key informant interviews also were conducted with partners to obtain 
external guidance on opportunities and challenges related to HIV, viral hepatitis, STD and TB 
prevention.  After NCHHSTP develops the draft Strategic Plan, the document will be shared and 
vetted with a broader group of partners and stakeholders. 
NCHHSTP launched a new “Prevention Through Health Care” website as an online resource to 
help leverage changes in the healthcare system at multiple levels:  state, local and tribal public 
health agencies, community-based organizations (CBOs), and other partners.  NCHHSTP 
published success stories and outcomes of demonstration projects related to its Program 
Collaboration and Service (PCSI) initiative. 
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A supplement on PCSI was published in the January 2014 edition of Public Health Reports.  
NCHHSTP published the 2013 Annual Report to highlight its center-wide activities and 
accomplishments.  NCHHSTP updated its “Atlas” with 2012 surveillance data for STDs and TB.  
All of these resources and publications are available on the CDC.gov/nchhstp website. 
NCHHSTP conducted a number of workforce development and capacity building activities.  A 
new seminar series on laboratory science was offered to epidemiologists.  A new scientific 
writing course was held for NCHHSTP scientists.  The Coaching and Leadership Initiative was 
piloted in 2013 with 60 team leaders.  NCHHSTP continued to conduct its Ambassador Program 
to assist new employees during their transition to the workforce. 
At the division level, the Division of HIV/AIDS Prevention (DHAP) published its first set of 
comprehensive clinical guidelines for pre-exposure prophylaxis (PrEP) on May 14, 2014.  The 
guidelines reflect extensive input from an internal CDC workgroup and external guidance from 
partners, providers, HIV patients and affected communities.  DHAP posted its revised HIV case 
definition on the CDC.gov website in April 2014. 
DHAP launched its new “Start Talking. Stop HIV” campaign on May 21, 2014 to encourage gay 
and bisexual men to openly discuss HIV in their relationships.  Dr. Mermin presented fact sheets 
that were developed for the campaign to emphasize the importance of safe and supportive 
relationships:  “Before the sweet nothings, whisper something that can keep him safe.”  “Talk 
before you play.”  “Make conversation before you make out.”  DHAP will conduct an evaluation 
in the future to determine the effectiveness of the campaign. 
DHAP awarded new “Capacity Building for High-Impact HIV Prevention” grants in April 2014 to 
21 organizations totaling $23 million.  Under the Category B-HIV Testing component of its 
funding opportunity announcement (FOA), the DHAP grants and guidance will help clinics and 
health departments to obtain reimbursement for provision of their services. 
DHAP released its 2013 National HIV Prevention Progress Report that highlighted the following 
outcomes:  62% of HIV targets were exceeded or met; 84% of persons living with HIV (PLWH) 
know their status; HIV incidence has decreased in heterosexuals, African American women and 
injection drug users (IDUs); and HIV incidence has increased in men who have sex with men 
(MSM). 
DHAP will soon release its HIV prevention recommendations for adults and adolescents living 
with HIV in the United States.  The guidelines will include several important features.  The 
national goal to decrease HIV incidence by reducing infectiousness and HIV exposure to others 
will be reinforced.  The need to consolidate all federal guidance on “prevention with positives” 
(PwP) will be emphasized.  New, effective and/or under-utilized interventions will be highlighted.  
The audience will be expanded to include clinicians, non-clinical providers, health departments 
and HIV planning groups.  Additional sections will be added to describe seven new topics. 
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DHAP’s next steps in releasing its HIV prevention recommendations will be to finalize the copy 
editing and document design, complete the HHS review and clearance process, and publish the 
guidelines on the CDC.gov website.  Links to the guidelines will be posted on a broad range of 
websites, including the CDC Morbidity and Mortality Weekly Report (MMWR), HRSA, AIDSinfo 
and other co-sponsor websites. 
The Division of Viral Hepatitis (DVH) closely collaborated with the American Association for the 
Study of Liver Disease (AASLD), Infectious Disease Society of America (IDSA), and the 
International Antiviral Society-USA in developing a new website (HCVguidelines.org) to provide 
practitioners who treat HCV-infected patients with the most up-to-date guidance on appropriate 
care.  The website features CDC’s published recommendations on HCV testing and linkage to 
care. 
DVH published two MMWR articles based on recent viral hepatitis studies.  The “Expanding 
Primary Care Capacity to Treat Hepatitis C Virus Infection Through an Evidence-Based Care 
Model in Arizona and Utah (2012-2014)” study analyzed the practices of 66 primary care 
clinicians with training in caring for HCV patients.  Most of the clinicians were from rural settings.  
Over the course of the study, 129 patients received antiviral treatment.  The study findings 
supported the expansion of HCV treatment in primary care settings, particularly since new 
therapies are far more effective, shorter in duration and much safer than previous treatment. 
The “Early Identification and Linkage to Care of Persons with Chronic Hepatitis B Virus 
Infection: Three U.S. Sites (2012-2014)” study described outcomes of hepatitis B virus (HBV) 
testing programs in New York City, Minneapolis-St. Paul and San Diego.  Of 4,727 persons 
tested at the three sites, 310 (or 6.6%) were hepatitis B surface antibody-positive.  Of 86% of 
the HBV-positive population that was referred to care, 66% attended their first scheduled 
medical visit. 
The Division of STD Prevention (DSTDP) published an MMWR article in March 2014 that 
updated CDC’s 2002 guidelines for laboratory-based screening tests to detect chlamydia and 
gonorrhea.  The new guidelines cover optimal specimen types, the use of specific tests to detect 
rectal and oropharyngeal infections, and supplemental testing.  The guidelines are available on 
the CDC.gov/std website for use by clinical laboratory directors and staff, clinicians and disease 
control personnel. 
DSTDP will release two new FOAs in the near future.  The five-year “National Network of STD 
Clinical Prevention Training Centers” FOA will be awarded in August 2014 to a maximum of 8 
regional and 6 national Centers of Excellence.  The grantees will be funded to develop, 
disseminate and evaluate technical assistance (TA) and training to improve STD care at the 
individual healthcare clinician, clinical organization and healthcare system levels.  The three-
year “Community Approaches to Reducing Sexually Transmitted Diseases” FOA will be 
awarded to advance community wellness, influence sexual health behaviors and practices, and 
reduce STD disparities. 
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The Division of Adolescent and School Health (DASH) will publish data from the Youth Risk 
Behavior Surveillance System in the June 12, 2014 edition of the MMWR.  DASH will convene 
the “Expert Panel on School-Based STD Screening Programs” on July 31-August 1, 2014.  The 
expert panel will be charged with achieving five overarching objectives. 
• Review published findings on adolescent and school health 
• Compare multiple models of school-community partnerships for program implementation 
• Consider factors and program characteristics that influence outcomes 
• Examine the cost of previous STD Screening Programs 
• Identify areas for future research and evaluation 
HRSA/HAB Associate Administrator’s Report 
Laura Cheever, MD, ScM 
Associate Administrator, HIV/AIDS Bureau 
Health Resources and Services Administration 
CHAC Designated Federal Officer, HRSA 
Dr. Cheever covered the following topics in her Associate Administrator’s report to CHAC.  HAB 
created a framework to describe the future direction of the Ryan White HIV/AIDS Program 
(RWHAP) in the context of the Affordable Care Act (ACA) and the evolution of the U.S. 
healthcare system over time. 
The framework is based on an overarching goal of achieving “zero new HIV infections” through 
a comprehensive system of care that incorporates a public health approach.  Successful 
treatment of patient reduces the risk of transmission of HIV by >90, demonstrating the role the 
RWHAP plays in ending the endemic through improving access to an outcomes of treatment.  
The RWHAP achieves these goals through service delivery, policy development, assessment, 
capacity development and quality improvement activities. 
HAB has greatly improved the availability and quality of RWHAP data.  The time period between 
refining and disseminating the Ryan White Services Report (RSR) was shortened from 12-18 
months to 6-9 months.  The AIDS Drug Assistance Program Data Report now reflects a client-
level data collection period of an entire calendar year.  The time period between refining and 
disseminating the report was shortened to 3-6 months.  State profiles of RWHAP funding now 
reflect client-level data across states, including viral load outcomes.  State data for 2012 will be 
released by the fall of 2014.  HAB data play a critical role in demonstrating the effectiveness of 
the RWHAP, monitoring grantee activities, and helping grantees to track outcomes and quality 
in their individual programs. 
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HAB is applying its data to innovative strategies to improve prevention and care outcomes.  The 
HAB/CDC partnership on HIV Care Continuum initiatives is ongoing to conduct the Care and 
Prevention in the United States Project, activities supported by the HHS Secretary’s Minority 
AIDS Initiative (MAI) Funding.  One Special Projects of National Significance (SPNS) Initiative in 
2014 will support clinics utilizing staff differently to improve outcomes along the continuum of 
care. 
A joint HAB/CDC meeting will be held with the National Alliance of State and Territorial AIDS 
Directors (NASTAD) to discuss opportunities and challenges in surveillance and program data 
integration and utilization.  Findings from the meeting will be used to improve HIV Care 
Continuum analyses and related activities.  Outcomes from the meeting also will benefit the 
FOA for a new SPNS Initiative that HAB will release in 2014 for states to link their surveillance 
data and RWHAP health outcomes data. 
HAB initiated integrated planning efforts with CDC.  HAB and CDC released a joint letter to their 
grantees to indicate ongoing support for integrated planning and alignment between HRSA’s 
RWHAP Comprehensive Plan/Statewide Coordinated Statement of Needs and CDC’s HIV 
Jurisdictional Prevention Plan.  HAB and CDC anticipate releasing integrated planning guidance 
to their grantees in 2015. 
HAB launched a new All Parts HIV Care Continuum Collaborative to improve access to HIV 
care and increase viral load suppression.  RWHAP grantees in Arkansas, Mississippi, Missouri, 
New Jersey and Ohio were funded to build statewide quality improvement (QI) collaborative 
teams.  This effort aims to achieve three goals:  (1) build regional capacity for closing gaps 
across the HIV Care Continuum to ultimately increase viral load suppression rates for PLWH; 
(2) align quality management goals across all RWHAP parts to jointly meet legislative quality 
management mandates; and (3) implement joint QI activities to advance the quality of care for 
PLWH within a state and seamlessly coordinate services across all RWHAP parts. 
HAB’s 2012 preliminary RSR data showed that HIV Care Continuum rates were higher in 
RWHAP than the national average.  Of all RWHAP clients who had at least one outpatient 
ambulatory medical care (OAMC) visit before September 1, 2012, 82% were retained in care 
(defined as having at least two visits >90 days apart).  Of all RWHAP clients who had at least 
one OAMC visit and at least one viral load count 75% were virally suppressed (defined as a last 
viral load test <200).  By risk group, retention in care rates were 82% for MSM, ~80% for black 
MSM (BMSM), and 74% for young MSM (YMSM) 13-24 years of age.  Viral suppression rates 
were 76% for MSM, ~68% for BMSM, and ~53% for YMSM. 
The 2012 preliminary RSR data emphasized the critical need to develop evidence based 
interventions (EBIs) to improve outcomes in adult and young BMSM.  HAB released a 
cooperative agreement (CoAg) for grantees to compile, distribute and replicate effective models 
of HIV clinical care and treatment for adult and young BMSM.  Year 1 of the CoAg will focus on 
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building an inventory of existing EBIs for HIV care and prevention.  Emphasis will be placed on 
areas of the nation where epidemiological data support the need for service delivery models. 
Grantees will conduct two major activities to achieve the year 1 goals.  A TA toolkit and 
workbook will be developed with effective, best-practice EBIs that can be replicated and 
implemented across the HIV Care Continuum for BMSM.  A web-based TA clearinghouse will 
be designed and linked to the HAB TARGET Center to assure optimal management of the 
inventory of TA resources (e.g., models of care, curricula, toolkits and webinars). 
Year 2 of the CoAg will focus on identifying and disseminating best practices and effective 
models of care for adult and young BMSM.  Grantees will conduct several activities to achieve 
the year 2 goals.  Comprehensive TA modules will be developed that will include procedural 
materials to enable providers to replicate and implement best practices and strategies for 
serving BMSM along the HIV Care Continuum. 
Dissemination of effective EBIs, strategies and models of HIV care will aim to increase the 
capacity, quality and effectiveness of HIV/AIDS service providers to screen, diagnose, link and 
retain both adult and young BMSM in HIV care.  Multiple platforms will be utilized to transfer 
knowledge and broadly disseminate models, strategies, best practices and all other resources:  
training manuals, webinars, curricula, and electronic and social media (e.g., Facebook, Twitter 
and blogs). 
To widely increase capacity to deliver services, enhance quality of care and improve health 
outcomes, dissemination efforts will be targeted to diverse audiences, including HIV/AIDS 
providers and stakeholders, health departments, Community Health Centers (CHCs), and 
federally and non-federally funded organizations.  HAB expects to award the CoAg for grantees 
to begin conducting activities on July 1, 2014. 
HAB will award a health literacy contract in FY 2014 to improve capacity of grantees to improve 
health literacy of their patients.  This effort is targeted to health departments and CBOs with and 
without RWHAP funding that provide HIV services to PLWH, particularly adult and young 
BMSM.  The contractors will offer a “train-the-trainer” course to multiple sites and the HAB 
TARGET Center and also will develop culturally appropriate health literacy materials (e.g., a 
web-based training manual and curriculum, tip sheets, posters and brochures).  A key feature 
will be to improve health insurance literacy so patients can take full advantage of expanded 
health care coverage.  
HAB will release two new CoAgs that focus on ACA implementation.  The goal of CoAg 1 is to 
increase the capacity of RWHAP core medical providers to initiate contacts with qualified health 
plans and facilitate enrollment of their clients into these health plans.  The goal of CoAg 2 is to 
assist non-medical AIDS Service Organizations (ASOs) to develop new service models in the 
rapidly evolving health financing landscape that will support the provision of critical services for 
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specific vulnerable populations to improve health outcomes through different stages across the 
HIV Care Continuum. 
HAB awarded contracts to conduct three ACA-related studies:  (1) “Emerging Issues Related to 
ACA Implementation and the Future of Ryan White Services: A Snapshot of Outpatient 
Ambulatory Medical Care;” (2) “Evaluating the Impact of 1115 Medicaid Waivers on the Ryan 
White HIV/AIDS Program and Its Clients and Providers;” and (3) “Understanding and Monitoring 
Funding Streams in Ryan White Clinics.”  Study 1 is underway.  Study 2 will be presented to 
HAB in May 2014 after the case studies have been completed.  Study 3 begun conducting 
interviews with 130 RWHAP Parts C and D grantees in April 2014.  The study will be completed 
in June 2014. 
HAB funded an Affordable Care Enrollment (ACE) TA Center.  To inform this new effort, an 
assessment was performed in the fall of 2013 to determine the needs of grantees in facilitating 
outreach and enrollment assistance to minority clients who sought private insurance through 
expansion of Medicaid or in the Marketplace.  An enrollment survey also was administered to 
RWHAP Parts A, B, C and D grantees.  Of 231 survey respondents, 31% received resources 
other than RWHAP funding to support outreach and enrollment efforts and 51% had staff with 
outreach and enrollment certifications within their organizations. 
Because needs of the survey respondents greatly varied by their Medicaid expansion status, 
insurance exchange type and enrollment capacity, HAB is aware of the need to tailor TA and 
training based on the specific needs of grantees and providers.  Many direct service providers 
reported their limited experience in and lack of knowledge of new ACA coverage options as well 
as their challenges in general outreach and enrollment. 
Several barriers to care were reported.  RWHAP providers reported that their minority clients 
who historically have faced barriers to accessing care were uncomfortable in enrolling in new 
ACA coverage options.  Clients particularly were concerned about the affordability of plans and 
the possibility of needing to change providers.  Issues were raised regarding the ability to 
maintain cultural competency in outreach and enrollment efforts to ensure RWHAP clients are 
retained in care in ACA coverage options. 
RWHAP grantees and providers emphasized the need for HAB to provide more local guidance 
on policies and best practices to improve communication and coordination.  Grantees and 
providers noted that gaps in coordination might have implications for care outcomes of their 
clients.  The ACE TA Center includes numerous resources for grantees.  Up-to-date strategies, 
tools, training, the Needs Assessment Report and other materials can be obtained by 
subscribing to the ACET TA Center listserve.  Questions can be posed directly to the ACE TA 
Center e-mailbox.  New resources and existing tools that are tailored, adapted and translated 
for RWHAP providers can be viewed on the ACE TA Center of the HAB TARGET Center. 
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HRSA is continuing to collaborate with CMS and the CMS Center for Consumer Information and 
Insurance Oversight (CCIIO) on key post-ACA enrollment issues, such as third-party payment 
monitoring, mail order pharmacies, prior authorization and Essential Community Provider 
implementation.  HAB’s post-ACA enrollment activities include responding to frequently asked 
questions by grantees; co-hosting webinars with CMS on best practices and other topics of 
relevance to RWHAP; assisting RWHAP grantees to assist clients in applying for and enrolling 
in healthcare coverage and educating RWHAP patients on the purpose of their health insurance 
coverage; and assuring RWHAP grantees are “in-network” with qualified health plans and 
Medicaid Managed Care Organizations. 
The FY2014 RWHAP enacted budget totals ~$2.3 billion with the AIDS Dug Assistance 
Program accounting for the largest proportion of the appropriations.  The FY2015 President’s 
budget proposed level funding for all RWHAP parts except for the consolidation of Parts C and 
D where a $4 million increase over FY 2013 for the consolidated budget was proposed.  The 
President’s budget recommended the consolidation of Parts C and D to improve the reach of 
the Women, Infants, Children and Youth program nationally across all Part C and D grantees 
and to reduce overlap in administrative burden between the two parts. 
HAB realigned its leadership and organizational structure in several areas.  The Director and 
Deputy Director of the Division of Policy and Data were appointed.  A search is underway to 
appoint a permanent HIV Education Branch Chief.  The Data Management and Analysis Branch 
reflects the consolidation of two previous branches.  The Clinical Unit was relocated to the new 
Program/Clinical Evaluation and Technical Assistance Branch.  The Organizational 
Development Team was relocated to the Office of Operations and Management.  A new branch 
was added to the Division of Community HIV/AIDS Program. 
CHAC discussed the following topics with Drs. Mermin and Cheever on the CDC and HRSA 
updates. 
• The ability of HRSA’s health literacy contractors to also provide education and resources 
to HIV-negative partners of RWHAP’s HIV-positive clients, particularly on PrEP and 
prevention as treatment interventions. 
• The exclusion of Latino, Asian and Native American MSM from new CDC and HRSA 
projects that are targeted to specific HIV risk groups. 
• HRSA’s efforts to ensure that geographic variations are addressed in the HIV Care 
Continuum Collaborative. 
• HRSA’s oversight and leadership to assure retention of a high level of competency for 
HIV and HCV care when RWHAP clients are required to change their providers in ACA 
coverage options. 
• The need for HRSA to expand RWHAP’s extraordinary success in HIV treatment to a 
much broader infectious disease program that would address PrEP for HIV-negative 
persons as well as comprehensive care, treatment adherence, drug-drug interactions 
and retention in care for HBV, HCV and STDs. 
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The discussion resulted in CHAC making several suggestions for CDC and HRSA leadership to 
consider in improving their agency-wide activities. 
• HRSA should provide leadership in ensuring that HRSA-funded state public health 
agencies, State Medicaid Directors and Marketplace Insurance Commissioners are 
extensively engaged in Statewide Coordinated Statement of Needs planning processes.  
Coordination and collaboration at the state level will be critical in increasing access to 
health care and improving health outcomes. 
• CHAC should set aside time during the Business Session to address two important 
questions:  (1) What is the obligation of HHS, CDC and HRSA to protect the health of 
the nation in a fair and equitable process?  (2) What is CHAC’s moral and ethical 
obligation to provide its expert advice to HHS, CDC and HRSA on combining categorical 
funding silos to benefit the health of the American public rather than bending to political 
pressures?  The FY2014 budgets reflect Congressional appropriations of ~$758 million 
to CDC for HIV/AIDS prevention activities and ~$2.3 billion to HRSA for RWHAP.  The 
tremendous amount of federal resources that has been targeted to HIV/AIDS prevention 
and treatment over time was needed to combat this deadly disease and achieve a 
significant public health impact.  However, CDC’s viral hepatitis budget of only $31 
million shows that the U.S. government does not view HCV as an urgent public health 
threat.  Based on its surveillance data, CDC reported a >50 increase in new HCV 
infections over the past five years and potential deaths of 897,000 persons with current 
HCV treatment rates.  As external expert advisors to HHS, CDC and HRSA, CHAC must 
now take a strong position to emphasize the critical need for more federal funding and 
efforts to HCV.  CHAC’s position statement should include future projections on the 
societal burden of HCV and CMS’s cost of paying for new HCV treatments. 
• CDC and HRSA should present data to educate Congressional staffers on the need to 
target more federal resources to HCV morbidity and mortality, but this effort should not 
result in a reduction of HIV prevention and treatment funding.  Most notably, 50,000 new 
HIV infections are still reported in the United States each year.  Moreover, HIV continues 
to be the leading cause of death in many states, including among African Americans 25-
54 years of age in Georgia. 
• HRSA’s ongoing efforts to improve the collection and dissemination of RWHAP client-
level data are commendable, but some CHAC members found HRSA’s investments in 
CAREWare to be “useless.”  HRSA designed CAREWare as a scalable software system 
for RWHAP grantees to manage and monitor their HIV clinical and supportive care 
services to patients and rapidly complete and submit their RSRs.  However, CAREWare 
has not maintained pace with current technology and capabilities of RWHAP providers in 
delivering HIV care.  An Institute of Medicine (IOM) expert committee released the 
Monitoring HIV Care in the United States: Indicators and Data Systems report.  The IOM 
report recommended the CDC Medical Monitoring Project (MMP) database in this effort, 
but did not even consider the HRSA CAREWare database as a resource.  HRSA should 
take actions to either dramatically modify or entirely eliminate CAREWare because the 
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database in its current form does not provide information on HIV quality outcomes and 
new performance measures. 
• CDC and HRSA should re-categorize and re-stratify non-IDUs substance use as a “high-
risk” group and develop concrete action plans for prevention, treatment adherence and 
retention in care for this population.  Non-IDU of crystal methamphetamines and other 
illegal substances has dramatically increased in HIV and HCV patient populations.  
Electronic health records (EHRs) will play a critical role in helping CDC and HRSA to 
systematically collect non-IDU data. 
• CHAC has no time for discussion after the 20-minute ACA presentation.  The agenda 
should be reorganized with sufficient time for CHAC to propose and vote on formal 
actions in response to important issues that have emerged since ACA was implemented 
in January 2014. 
o HIV providers have begun to report lower rates of retention in care and viral load 
suppression in their patients due to much higher co-pays for HIV medications under 
ACA. 
o ACA explicitly prohibits the denial of insurance coverage based on preexisting 
conditions.  However, some insurance companies are using a “grandfather” clause 
to retain their pre-ACA restrictions on preexisting conditions and continue to deny 
coverage to HIV patients.  This trend is particularly affecting African Americans and 
Hispanics with late-stage HIV diagnoses. 
o Some insurance carriers are eliminating HIV providers from their networks due to the 
perception that these providers will have poor performance outcomes based on ACA 
requirements. 
Drs. Mermin and Cheever responded to CHAC’s comments and concerns regarding the tension 
between HIV and HCV.  CHAC is chartered to advise HHS, CDC and HRSA on objectives, 
strategies, policies and priorities for HIV, viral hepatitis and STD prevention and treatment 
efforts for the nation.  Decision-making on appropriations is the responsibility of Congress rather 
than Federal Advisory Committees.  HHS, CDC and HRSA must allocate their appropriations as 
mandated by Congress to achieve the greatest public health impact. 
The tremendous amount of federal funding that has been allocated to HIV prevention and 
treatment over time has resulted in significant public health progress.  Prevention resources 
have decreased the incidence of new HIV infections, while treatment resources have allowed 
the current HIV-positive population of ~1.2 million persons in the United States to live with rather 
than die from HIV.  The redirection of resources from HIV to HCV could result in unforeseen 
adverse consequences for public health overall. 
Drs. Mermin and Cheever asked CHAC to consider opportunities to make similar progress in 
HCV by applying HIV lessons learned, building on HIV successes, and leveraging existing 
systems.  For example, CHAC could explore changes in the healthcare systems to advise CDC 
and HRSA on creating new guidelines, initiating new program activities, or targeting resources 
to expand HCV prevention and treatment.  Most notably, the availability of new all-oral, non-
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interferon-based agents for HCV will allow HRSA-funded CHCs and RWHAP grantees to 
maximize their investments in the treatment of HIV/HCV co-infected patients. 
Panel Presentation: Improving Screening and Treatment of Chronic Hepatitis C 
CDC and HRSA presented updates on their recent activities to improve screening and treatment 
of chronic HCV.  The updates are set forth below. 
Advice Requested from CHAC by DVH and HAB: 
1. What existing and new strategies should CDC consider and prioritize to increase the 
number of persons tested and cured of HCV? 
2. What strategies can HRSA implement to address challenges related to screening and 
providing care to persons with HCV?  What approaches can HRSA take to expand access 
to screening and treatment to persons in most need of these services? 
3. What is the potential for new developments in HCV screening and treatment to change the 
provision of HCV care?  Will these new developments give greater opportunities for 
primary care providers (PCPs) to diagnose and treat HCV? 
4. What actions can HRSA take to leverage primary care medical homes, ACA mandates and 
Accountable Care Organization (ACO) resources to improve access to viral hepatitis 
screening, care and treatment? 
5. What strategies can HRSA implement to streamline viral hepatitis care and treatment in 
the context of new and simpler regimens? 
John Ward, MD 
Director, NCHHSTP Division of Viral Hepatitis  
Centers for Disease Control and Prevention 
Dr. Ward described CDC’s strategies to improve the diagnosis, care and treatment of HCV.  
CDC and the U.S. Preventive Services Task Force (USPSTF) updated their recommendations 
on HCV testing to assure consistency in three areas.  First, a one-time test is recommended for 
all persons born in 1945-1965 due to the five-fold higher prevalence of HCV in this birth cohort. 
Second, HCV testing is recommended for specific risk groups:  persons with past or present 
IDU, persons who received blood transfusions or organ transplants prior to June 1992, persons 
who were ever on chronic hemodialysis, and persons with a history of incarceration.  Third, HCV 
testing is recommended for persons with medical indications, such as patients with persistent 
evidence of liver disease and patients with HIV or other important co-morbidities. 
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Several studies conducted in 2012-2013 demonstrated that the linkage between HCV testing of 
the 1945-1965 birth cohort and optimal care and treatment of this population would be cost-
effective and generate profound health benefits.  Full implementation of the CDC and USPSTF 
HCV testing guidelines would result in a dramatic reduction in liver cancer risks and mortality:  a 
90% decrease in liver-related mortality, a 70% decrease in hepatocellular carcinoma, a 50% 
decrease in all-cause mortality, and prevention of >120,000 HCV-related deaths.  Multiple 
studies reported the cost-effectiveness of full implementation of the CDC and USPSTF HCV 
testing guidelines in the general population (e.g., $15,700-$85,300 per quality-adjusted life-year) 
and also in settings with a low HCV prevalence of >0.84%. 
Additional benefits of the linkage between HCV testing and care/treatment will be gained as 
HCV therapy evolves over time.  Most notably, licensure of Sofosbuvir and Simeprevir by the 
U.S. Food and Drug Administration (FDA) has introduced a new era of all-oral HCV therapy that 
will result in higher cure rates.  Based on clinical trial data, completion rates of >90% were 
reported because the new drugs eliminated barriers related to the level of disease and specific 
HCV genotypes. 
Despite this progress, efforts are still needed to improve the quality of HCV management in 
order for patients to benefit from therapy.  Of 3.2 million persons living with HCV in the United 
States, only 50% receive anti-HCV testing.  Of persons who are tested, only 38% are linked to 
care.  Of persons in care, only 23% receive follow-up HCV RNA testing.  Of persons who 
receive follow-up testing, only 11% are treated.  Of persons who are treated, only 6% achieve a 
sustained virologic response (SVR) (i.e., cure).  These data indicate the ongoing challenge to 
improve the HCV care continuum to ensure testing achieves the maximum public health benefit 
of reducing morbidity and mortality. 
CDC’s public health role in the HCV testing-to-cure continuum at the national level is to provide 
leadership, resources and support to state and local partners.  The 1988 IOM report identified 
assessment, policy development and assurance as the three overarching goals in any public 
health framework.  Specific activities to achieve the public health goals and inform system 
management and research also were highlighted in the IOM report:  monitor heath; diagnose 
and investigate; inform, educate and empower; mobilize community partnerships; develop 
policies; enforce laws; link to and provide care; assure a competent workforce; and evaluate 
outcomes. 
CDC is applying the three public health goals as the basis to improve HCV testing, care and 
treatment.  For the “assessment” goal, CDC created a new database to monitor implementation 
of national HCV testing policies based on data submitted by U.S. commercial laboratories.  For 
example, the number of HCV tests that LabCorp conducted in 2013 increased by ~22% 
following the release of CDC’s guidelines in 2012.  CDC’s new database also is designed to 
capture other attributes that will be important for HCV monitoring (e.g., the number of HCV-
positive persons nationally, types of providers based on their specialty, and state/local 
geographic locations of patients and providers based on their zip codes). 
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CDC is continuing to assist states with standard case surveillance, but many jurisdictions are 
overwhelmed with and have limited capacity to address the number of new HCV cases.  Most 
notably, >30 states reported a >50% increase in new HCV infections in the 2007-2012 time 
period.  Several studies have described the demographics of persons with new HCV diagnoses:  
~70% IDUs, young persons 18-29 years of age with equal distribution between males and 
females, predominately white persons in non-urban, suburban areas, and previous users of 
prescription drugs. 
For the “health policy development” goal, CDC was a major contributor to the updated HHS 
Action Plan for the Prevention, Care and Treatment of Viral Hepatitis (2014-2016) (VHAP).  The 
updated version of VHAP outlines six national priorities for viral hepatitis. 
• Educate providers and communities to reduce health disparities 
• Improve testing, care and treatment to prevent liver disease and cancer 
• Strengthen surveillance to detect viral hepatitis transmission and disease 
• Eliminate transmission of vaccine-preventable viral hepatitis 
• Reduce viral hepatitis cases associated with drug-use behaviors 
• Protect patients and workers from healthcare-associated viral hepatitis 
CDC sponsored the development of new joint AASLD/IDSA policies for HCV treatment in the 
United States that were released in February 2014 (www.hcvguidelines.org) in response to FDA 
licensure of Sofosbuvir and Simeprevir.  The AASLD/IDSA joint policies include guidance on all-
oral treatments for HCV genotypes 1, 2 and 3.  Other new HCV agents have been filed and are 
expected to be licensed by FDA by December 2014.  However, the cost of the new HCV drugs 
will be an issue. 
For the “assurance” goal, CDC and its federal, state, academia and professional association 
partners are conducting numerous activities to guide HCV testing and assure linkage to care.  
Several states used CDC’s recommendations to introduce and/or pass public health legislation 
to promote HCV testing.  Colorado, Connecticut and New York passed laws in 2013-2014 that 
now require or encourage providers in primary care and in-patient settings to offer HCV testing 
to all persons in the 1945-1965 birth cohort.  Similar HCV testing legislation is pending in 
California, Illinois, Massachusetts, New Jersey and Pennsylvania.  HCV testing legislation was 
defeated in Florida, Maryland and Oklahoma.  The CDC Public Health Law Program is exploring 
the development of a toolkit to assist states in using the HCV testing recommendations to create 
model legislation. 
CDC is assuring a competent workforce by funding provider training in testing and clinical 
management of HBV and HCV.  An online HCV training course is available on the University of 
Washington website (http://hepatitisc.us.edu).  The Primary Care Liver Program was developed 
by the American College of Physicians and AASLD and is available on the AASLD website 
(www.aasld.org).  Viral hepatitis prevention coordinators are funded to provide training in 48 
states and 4 cities. 
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CDC allocated ~$1.5 million to the “No More Hepatitis” public education campaign to widely 
publicize messages on billboards, airport diorama, radio public service announcements and 
videos.  For example, the Times Square Jumbotron featured continuous HCV messages for two 
weeks in May 2014 to inform the public that HCV is a health threat for persons in the 1945-1965 
birth cohort.  A cost assessment showed that $12 of space is donated for each $1 CDC spends 
on the campaign. 
CDC allocated additional resources that the HHS Secretary awarded from the Prevention and 
Public Health Fund to conduct HCV testing and linkage to care demonstration projects at CHCs.  
From October 1, 2012-March 31, 2014, CHCs in seven cities were funded to perform HCV 
testing and report the following outcomes. 
• Total number of persons tested (a range of 1,234 to 6,093 persons) 
• Percentage of current infections based on HCV antibody-positive and HCV RNA-positive 
test results (a range of 3% to 37%) 
• Percentage of persons referred to care (a range of 60% to 100%) 
• Percentage of persons who attended their appointments (a range of 15% to 100%) 
The demonstration projects showed that the most successful CHCs were not required to ensure 
linkage to care because HCV testing and care occurred in the same facility.  In future FOAs, 
CDC will make strong efforts to replicate the approach in which PCPs will perform HCV testing 
and provide care in the same setting. 
CDC published an MMWR article on May 9, 2014 to report outcomes of care models that the 
Arizona and Utah Project ECHO® sites (Extension for Community Healthcare Outcomes) 
implemented in 2012-2014.  Project ECHO® is a telemedicine-based knowledge network that 
links PCPs in predominantly rural settings with specialists.  Of 66 PCPs who were trained by the 
Arizona and Utah sites, 93% had no previous experience in HCV care.  The provision of antiviral 
treatment to 46% of HCV-positive patients was more than twice the proportion observed in other 
CDC studies.  These findings demonstrate the utility of the Project ECHO® model in expanding 
HCV care and treatment capacity. 
The CDC Foundation provided support to develop the Viral Hepatitis Action Coalition that has 
raised $27 million since 2011 for CDC to conduct numerous viral hepatitis activities, including 
evaluation projects, policy implementation initiatives, research, development of clinical decision 
tools, the “No More Hepatitis” campaign, and events for state and local stakeholders. 
CDC used a portion of its $9 million increase in the viral hepatitis budget to release the new 
“Community-Based Programs to Test and Cure Hepatitis C” FOA.  The goal of the new CoAg 
will be for grantees to build community coalitions that will implement a package of services to 
strengthen healthcare capacity to diagnose and cure HCV.  CDC expects to award a total of $20 
million to three grantees at an average of $1.5 million annually over the four-year project period.  
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The deadline to submit applications was May 20, 2014.  CDC will announce the award on 
August 31, 2014. 
The FOA outlines specific requirements for grantees.  Public health partners, care specialists 
and PCPs must be included in community coalitions.  The package of services that will be 
developed and implemented must include provider education resources, models of care (e.g., 
Project ECHO®), physician reminders and other clinical decision tools, performance measures, 
and registries or other data systems to measure impact. 
CDC will use long-term outcome indicators to evaluate progress of the grantees in three areas:  
(1) an annual increase in anti-HCV testing of >50% or at least 10,000 persons, whichever is 
greater; (2) an annual increase of >50% or at least 2,000 persons, whichever is greater, in the 
number of persons diagnosed with current HCV infection; and (3) an annual increase of >50% 
or at least 2,500 persons, whichever is greater, in the number of HCV-infected persons cured of 
their infection. 
Overall, CDC’s strategies to improve HCV testing, care and cure are based on three goals in the 
public health framework.  For the assessment goal, CDC is monitoring and investigating HCV 
infections nationally.  For the health policy development goal, CDC is gathering and evaluating 
evidence, establishing national priorities to prevent HCV transmission and disease, guiding 
prevention programs, and mobilizing partnerships.  For the assurance goal, CDC is supporting 
and evaluating programs, assessing policy implementation in the health system, training the 
workforce, and educating communities.  CDC is now shifting its focus to capacity building to 
ensure that its strategies are successful in improving HCV diagnosis, care and treatment. 
Rupali Doshi, MD, MS 
Medical Officer, HIV/AIDS Bureau 
Health Resources and Services Administration 
Dr. Doshi described HRSA’s activities to expand access to quality HCV care and treatment.  
HAB and six other HRSA bureaus and offices contributed to updating VHAP for 2014-2016 and 
are conducting activities to support the six VHAP priorities identified by the HHS Secretary. 
VHAP priority 1 is to educate providers and communities to reduce health disparities.  HRSA 
disseminates educational materials to providers and communities.  Support is provided to tele-
health programs that target viral hepatitis education among safety net providers in HRSA-
funded AIDS Education Training Centers (AETCs).  CoAgs were awarded to several CBOs to 
increase the reach of HRSA’s information dissemination and educational activities:  Association 
of Asian Pacific Community Health Organizations, LGBT Health Education Center, National 
Association of Community Health Centers (NACHC), and National Health Care for the 
Homeless Council.  National Hepatitis Day was widely promoted. 
VHAP priority 2 is to improve testing, care and treatment to prevent liver disease and cancer.  
HRSA promotes adherence to national guidelines for hepatitis screening, treatment and linkage 
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to care.  SPNS Initiatives were awarded to support PCPs in becoming hepatitis treatment 
providers.  Health insurance enrollment is promoted to increase access to viral hepatitis care 
and treatment. 
VHAP priority 3 is to strengthen surveillance to detect viral hepatitis transmission and disease.  
HRSA promotes reporting of newly-diagnosed viral hepatitis cases to state and local health 
departments (SHDs and LHDs). 
VHAP priority 4 is to eliminate transmission of vaccine-preventable viral hepatitis.  HRSA 
promotes HBV testing among pregnant women and provides appropriate referrals for care and 
treatment.  Compliance with the Advisory Committee on Immunization Practices vaccination 
recommendations for hepatitis A virus and HBV is promoted. 
VHAP priority 5 is to reduce viral hepatitis cases associated with drug-use behaviors.  HRSA 
supports screening, care and treatment of viral hepatitis in opioid treatment and syringe services 
programs.  Linkages with correctional settings are promoted to assure continuity of viral 
hepatitis care and treatment when newly released persons reenter the community. 
VHAP priority 6 is to protect patients and workers from healthcare-associated viral hepatitis.  
HRSA promotes infection control with safety net providers.  Collaborative efforts are undertaken 
with the Organ Procurement and Transplantation Network (OPTN) to revise existing OPTN 
policies to assure consistency with CDC guidelines, such as implementation of nucleic acid 
testing for HCV among organ donors.  HBV vaccination among healthcare workers is promoted. 
HRSA also is conducting several other HCV care and treatment activities beyond those that are 
supporting the six VHAP priorities.  HRSA is collaborating with CDC on the HHS Secretary’s 
“MAI Funding to Increase HIV Prevention and Care Service Delivery Among Health Centers 
Serving High Prevalence Jurisdictions.”  Under this project, health department/Health Center 
partnerships will be funded in four states to build Health Center capacity to provide prevention, 
testing, care and treatment to PLWH.  The project also will support hepatitis screening and 
referral to care due to the high level of HIV/HCV co-infection. 
HRSA awarded funds to AETCs to support nine demonstration projects at Tele-Health Training 
Centers.  The project is targeted to low-volume healthcare providers who serve PLWH in 
historically underserved communities.  The project aims to expand access to and improve 
health care for hard-to-reach PLWH in medical care.  Key features of the project include clinical 
consultation, education and training utilizing tele-health technology, and development of an 
informed support system for trainees.  The AETCs were asked to provide additional training to 
the Tele-health Training Centers to focus on the HIV co-morbidities of HCV and behavioral 
health. 
HRSA awarded the SPNS HCV Treatment Initiative to support demonstration projects at 29 
comprehensive HIV clinics.  Over the two-year project period, the grantees will implement one 
 
Meeting Minutes: CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment 
May 21-22, 2014 ♦ Page 21 
 
of four models of HCV care for HIV/HCV co-infection:  integrated HCV care, designated HCV 
clinic sessions, HCV care delivery by a PCP with expert backup, or referral to an outside 
specialist for care. 
Preliminary data from the SPNS HCV Treatment Initiative show that of 223 patients who began 
HCV treatment, 195 (or 87.4%) completed treatment and 99 (or 44.4%) achieved an SVR.  A 
dedicated patient tracker was instrumental in assuring linkage to and retention in care.  Ongoing 
TA through monthly didactic and case-based webinars, site visits and as-needed clinical 
consultation from the Evaluation and Technical Assistance Center increased the confidence of 
providers in initiating care. 
HRSA’s Uniform Data System (UDS) showed increases in the numbers of patients Health 
Centers served from 2011 to 2012:  from 94,605 to 114,881 HIV patients; from 11,108 to 21,890 
HBV patients; and from 61,294 to 132,078 HCV patients. 
The HRSA Bureau of Primary Health Care’s (BPHC) national partners developed several 
resources and offered numerous trainings on hepatitis-related issues that were targeted to key 
risk groups, including MSM, homeless persons, the lesbian/gay/bisexual/transgender (LGBT) 
community, Asians/Pacific Islanders, and CHC and primary care patient populations. 
The HRSA Office of Regional Operations is strengthening its strategic regional partnerships to 
further expand access to quality HCV care and treatment.  HRSA’s regional offices in Boston, 
Denver and New York promoted HCV education for PCPs in collaboration with partners, helped 
to plan the Viral Hepatitis Summit, and participated in the HHS VHAP Stakeholder meeting. 
Overall, HRSA will continue to address key challenges to increasing HCV linkage to care and 
treatment.  These issues include the small number of providers with HCV training, the high cost 
of HCV drugs, the absence of a care system for HCV-positive patients with dedicated funding, 
and competing priorities for PCPs. 
CHAC discussed the following topics with Drs. Ward and Doshi on ongoing activities by CDC 
and HRSA to improve chronic HCV screening and treatment. 
• Concerns expressed by non-Medicaid expansion states in paying for treatment of HCV-
positive patients, particularly since the market price for a curative regimen of Sofosbuvir 
is ~$84,000 (or ~$1,000 per pill). 
• The failure of New York State legislators to allocate new funding to support training, 
public information dissemination and other necessary activities for state public health 
and healthcare providers to implement the new HCV testing law in the field. 
CHAC applauded Dr. Ward for his national leadership in elevating the profile of viral hepatitis, 
advancing the field, and galvanizing strong support for HCV despite tremendous budget 
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constraints.  Several CHAC members made suggestions for CDC and HRSA to consider in 
improving national HCV screening and treatment efforts. 
• HCV screening and treatment should be tied to payment and CMS’s Meaningful Use 
indicators in the healthcare system.  Clinics and providers also should be given reports 
of their performance in these areas on a routine basis.  Based on past experiences with 
HIV quality measures, incentives must be offered in order for PCPs to adhere to and 
fully implement HCV testing and treatment guidelines.  
• The public health model for TB should be replicated for the HCV testing-to-cure 
continuum, particularly since new drugs have improved the safety and efficacy of HCV 
therapy.  Health departments are responsible for ensuring that TB patients are followed 
from the time of their diagnosis to achievement of a microbiologically-proven cure. 
• Successes, failures and lessons learned over the evolution of the HIV epidemic should 
be thoroughly reviewed and applied to HCV screening and treatment. 
o The media extensively covered, widely publicized and promoted the success of new 
antiretroviral (ARV) drugs for “nearly dead” HIV patients.  The same level of media 
coverage should be used to convey personal stories of HCV patients who are 
completing treatment and being cured with new drugs that are safer and more 
effective.  Similar to HIV, constant media attention could help to increase awareness, 
visibility and advocacy for HCV testing and treatment at the community level. 
o Cost-effectiveness data and other rigorous evidence were collected to justify the 
need for more HIV funding at federal and state levels.  The same approach should 
be taken for HCV.  Based on CDC data, for example, full implementation of the HCV 
screening policy for the 1945-1965 birth cohort could result in cost-savings of $1.5 
billion to the healthcare system.  Moreover, the difference in healthcare costs 
between HCV treatment and a liver transplant is large (e.g., $84,000 versus 
$500,000). 
o The original public health strategy of creating “HIV exceptionalism” with distinct 
screening and care sites and a separate provider workforce has been a mistake in 
hindsight.  CDC’s PCSI Initiative and other federal efforts to combine HIV with other 
infectious and chronic diseases have resulted in minimal and slow progress to date.  
Public health should not repeat the same mistake with HCV.  Ongoing efforts to 
transition to a more comprehensive and holistic patient-centered medical home 
(PCMH) model should continue.  Full integration of screening and treatment for HIV, 
HCV, STDs, substance abuse and mental health issues into primary care settings 
will increase access and obtain evidence base for strong leadership and support for 
this public health approach.  Resources should now be invested to apply the TasP 
strategy to HCV and rapidly deliver new HCV drugs to persons in need.  Healthcare 
costs associated with complications and long-term follow-up of HCV patients can be 
avoided if treatment is initiated immediately after acquisition of disease. 
Analysis Results: New Coverage for PLWH Due to the Affordable Care Act 
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Jennifer Kates, PhD 
Vice President & Director, Global Health and HIV Policy 
Kaiser Family Foundation 
CHAC Member & Data Workgroup Chair 
Dr. Kates presented the results of a new analysis conducted by the Kaiser Family Foundation 
(Kaiser) and researchers at the Centers for Disease Control and Prevention (CDC) to estimate 
the number of PLWH who could gain new coverage under ACA.  The ACA will expand 
insurance coverage for millions of persons in the United States, including PLWH.  The 
expanded coverage will occur in states that have chosen to expand Medicaid and through new 
Health Insurance Marketplaces available in all states for individuals to purchase coverage, 
including subsidies for those who are lower incomes.  Despite the importance of the ACA for 
people with HIV, there were no national estimates of the number of people with HIV likely to 
gain new insurance coverage due to ACA. 
Kaiser and CDC undertook an analysis to develop such estimates, and issued a joint report in 
January 2014, Assessing the Impact of the Affordable Care Act on Health Insurance Coverage 
of People with HIV, to fill this data gap.  The study design and methodology are summarized as 
follows.  Data from the CDC MMP were analyzed.  MMP is a supplemental HIV surveillance 
system that produces nationally representative estimates of behavioral and clinical 
characteristics of HIV-infected adults who receive medical care in the United States.  The IOM 
recommended the use of MMP to monitor the impact of ACA. 
The analysis utilized 2009 MMP data of adult PLWH 19-64 years of age who were in care to 
estimate pre-ACA insurance and income status.  The sample size of 4,067 PLWH in care 
represented an estimated national population of 406,970 PLWH (but did not represent the full 
population of all people with HIV including those not yet diagnosed or in regular care.   
Insurance status was examined by income and whether individuals with HIV received support 
from the Ryan White HIV/AIDS Program.  The number of PLWH who could gain new Medicaid 
coverage or subsidized coverage through Health Insurance Marketplaces was estimated.  The 
impact of state decisions on Medicaid expansion was described.  Key findings of the analysis 
include the following: 
• Insurance coverage of 406,970 non-elderly adult PLWH who were in care in 2009 
o Medicaid: 41% 
o Private insurance: 30% 
o Uninsured: 17% 
o Medicare: 6% 
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o Other public sources: 5% 
o RWHAP support (of those with and without insurance): 4 out of every 10 clients 
• Income distribution of 406,970 non-elderly adult PLWH who were in care in 2009 
o <100% of the Federal Poverty Level (FPL): 44% 
o 100%-138% of the FPL: 17% 
o 139%-399% of the FPL: 26% 
o >400% of the FPL: 13% 
• Income distribution of 69,720 uninsured non-elderly adult PLWH who were in care in 
2009 
o <100% of the FPL: 51% 
o 100%-138% of the FPL: 16% 
o 139%-399% of the FPL: 29% 
o >400% of the FPL: 4% 
Based on the income distribution data, virtually all 69,720 uninsured non-elderly adult PLWH 
would benefit from new coverage if all states chose Medicaid expansion.  At this time, 27 
Medicaid expansion states (including the District of Columbia) account for 57% of PLWH, while 
24 non-Medicaid expansion states that primarily are in the South account for 43% of PLWH (or 
>4 out of every 10 PLWH).  In the non-Medicaid expansion states, new Medicaid coverage or 
subsidized coverage through Health Insurance Marketplaces will not be available to 22% of 
PLWH <100% of the FPL (or 15,460 persons) and 7% of PLWH at 100%-138% of the FPL (or 
4,890 persons). 
Overall, ~70,000 uninsured PLWH who currently are in care could gain new coverage under 
ACA, but this estimate would increase to ~200,000 with the inclusion of PLWH who are not yet 
in care.  Decisions by states regarding Medicaid expansion will have significant implications.  
The number of PLWH who are newly eligible for Medicaid would be reduced by >40% given the 
number of states that have decided not to move forward with Medicaid expansion at this time. 
Moreover, most PLWH with incomes <100% of the FPL in non-expansion states will not be 
eligible to obtain subsidized coverage through Health Insurance Marketplaces because they fall 
into the “coverage gap”.  The implementation of ACA has not diminished the critical role of 
RWHAP in covering services for PLWH, particularly those in non-Medicaid expansion states 
and those with new or existing coverage who will need additional services due to out-of-pocket 
costs.  Kaiser and CDC are exploring the possibility of conducting additional analyses in the 
future due to the expansion of MMP, but CHAC’s input on approaches to strategically and 
effectively disseminate the report to key target audiences would be welcome. 
CHAC pointed out that it was interested in identifying recommendations that could be provided 
to states about the best way to use RWHAP resources in the current ACA environment.  Such 
recommendations would need to be state-specific; national guidelines would not be useful in 
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this regard.  The CHAC agreed to revisit this issue at a future meeting to discuss ways to assist 
HRSA in developing state-specific guidance, especially in states that are not expanding 
Medicaid. 
Panel Presentation: Innovative HIV Prevention Approaches for 
MSM and Other At-Risk LGBT Populations 
A panel of speakers presented a series of overviews on innovative HIV prevention approaches 
that are being implemented for MSM and other at-risk LGBT populations.  The overviews are 
set forth below. 
Advice Requested from CHAC by NCHHSTP:  
1. What are the best strategies to identify MSM who are eligible for and at greatest need of 
PrEP? 
2. What are the optimal settings to provide PrEP to MSM (e.g., HIV providers, STD clinics or 
MSM-focused clinics)? 
3. What steps can CDC take to encourage providers at specific sites to offer PrEP to eligible 
MSM? 
4. Due to the importance of STDs in facilitating HIV transmission and acquisition, what 
strategies can CDC implement to reduce syphilis and gonorrhea rates among MSM, 
particularly among MSM who use TasP and PrEP to prevent HIV? 
5. What are the best models to increase syphilis and gonorrhea screening among MSM? 
6. Due to limited funding, should CDC’s efforts to improve sexual health and HIV/STD 
prevention education be generalized for all students or focused on youth at a 
disproportionate risk (e.g., LGBT youth and YMSM)? 
7. What are the top 2 activities that schools should prioritize to create a safe and supportive 
environment for LGBT youth and YMSM? 
8. What are reasonable expectations of sexual health services provided by School-Based 
Health Clinics (SBHCs) or school nurses for all youth, including LGBT youth and YMSM? 
Amy Lansky, PhD, MPH 
Deputy Director for Surveillance, Epidemiology and Laboratory Sciences 
Division of HIV/AIDS Prevention, NCHHSTP 
Centers for Disease Control and Prevention 
Dr. Lansky presented an overview of CDC’s Preexposure Prophylaxis for the Prevention of HIV 
Infection in the United States-2014 Guidelines that were released on May 14, 2014.  The 
guidelines are for clinicians and provided recommendations on prescribing PrEP. 
The PrEP guidelines include several overarching recommendations.  Daily oral PrEP with 
Truvada® is recommended as one prevention option for sexually active MSM, sexually active 
heterosexual men and women, and IDUs at substantial risk for HIV infection.  In addition, the 
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use of PrEP during conception and pregnancy should be discussed with HIV-discordant couples 
wanting to become pregnant. The use of PrEP should be carefully weighed for adolescent 
minors.  Acute or established HIV infection and renal compromise should be excluded prior to 
initiation and regular use of PrEP.  Medication adherence and risk reduction practices should be 
supported throughout the use of PrEP. 
For this presentation, Dr. Lansky highlighted specific recommendations for MSM.  Daily oral 
PrEP with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is recommended as one HIV 
prevention option for sexually active MSM who are at substantial risk of HIV acquisition.  This 
guidance is based on evidence from the iPreX PrEP clinical trial which demonstrated the safety 
and efficacy of PrEP in MSM, particularly when medication adherence was high. 
Indications for PrEP use among MSM include risks such as having an HIV-positive sexual 
partner, recent bacterial STD, high number of sex partners, history of inconsistent or no condom 
use, or commercial sex work. Indications for PrEP use among heterosexual men and women 
are include having an HIV-positive sexual partner, recent bacterial STD, high number of sex 
partners, history of inconsistent or no condom use, commercial sex work, or location in a high-
prevalence area or network.  Indications for PrEP use among IDUs include having an HIV-
positive drug-injecting sexual partner; sharing of drug injection equipment; and recent drug 
treatment, but continued IDU. 
The PrEP guidelines include several resources that will be useful to providers.  Examples of risk 
assessment questions and tools are provided in the guidelines.  The PrEP guidelines include 
specific recommendations for adolescents.  Clinicians who are considering providing PrEP to a 
minor should be aware of local laws, regulations and policies that may apply.  Because none of 
the completed PrEP clinical trials included persons <18 years of age, clinicians are urged to 
carefully consider three important issues:  (1) the lack of data on the safety and efficacy of PrEP 
taken by persons <18 years of age; (2) the possibility of bone or other toxicities among youth 
who are still growing; and (3) available safety evidence when Truvada® is used as a treatment 
regimen for HIV-infected youth. 
The PrEP guidelines include a supplement for clinical providers with patient fact sheets on 
PrEP, Truvada® and acute HIV infection and PrEP.  Materials for providers include a patient/ 
provider checklist; information on PrEP during conception, pregnancy and breastfeeding; an HIV 
incidence risk index for MSM; billing codes; potential PrEP practice quality measures; and 
supplemental counseling information.   
The PrEP clinical trials raised several issues that will be critical to implementation.  Safety 
monitoring will continue to be important in actual practice in the field.  Healthcare providers who 
are not HIV specialists will need extensive education on administering PrEP in the following 
areas:  discussing the benefits and risks of PrEP with patients; initiating and monitoring PrEP to 
minimize toxicity and maximize effectiveness; discussing and supporting adherence and risk 
reduction strategies; and managing HIV infection if the disease is acquired.   
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In response to FDA’s post-marketing requirements regarding further study of adherence to 
PrEP, CDC, the CDC Foundation and Gilead Sciences established a public/private partnership 
to launch the “Sustainable Health Center Implementation PrEP Pilot” (SHIPP) Study.  This is a 
pilot study of PrEP implementation in community health centers (CHCs).  The SHIPP sites are 
located in underserved communities with high rates of HIV infection:  Chicago, Houston, Newark 
and Philadelphia. SHIPP was designed as a health services observational cohort.  CHCs to 
collect de-identified data from medical records and evaluate prescribing practices, patient 
outcomes and service costs for all patients who receive PrEP.  The SHIPP Medication 
Adherence Sub-Study collects dried blood spots to measure drug levels, and provides 
adherence aids to patients with sub-optimal adherence.  CDC will fund the “Context Matters” 
study in the SHIPP communities to assess attitudes and knowledge about PrEP among 
clinicians, key stakeholders and laypersons. 
PrEP costs can be addressed in several ways.  The average retail pharmacy price for a one-
month supply of Truvada® is $1,400, but payment of the full price is rare.  Price reductions have 
been negotiated.  Most private employers, school-based insurance carriers, Medicaid and other 
public insurers cover PrEP medication and care.  PrEP drug and co-pay assistance programs 
are available.  PrEP is offered to persons with low incomes or no insurance coverage at no 
charge.   
One study by Rawlings, et al. (2013) estimated early PrEP uptake using U.S. retail pharmacy 
claims data.  The dataset was estimated to represent 55% of PrEP prescriptions in the United 
States.  PrEP prescribers in ~700 cities across 49 states included family practice and internal 
medicine physicians (31%), nurse practitioners, physician assistants or other non-physicians 
(17%), emergency medicine physicians (14%), and infectious disease physicians (12%).  The 
study reported an 8.5-fold increase in the number of PrEP prescriptions from 150 in 2011 to 
1,274 in 2012.  Women accounted for 48% of prescriptions and persons <25 years of age 
accounted for 14% of prescriptions. 
CDC is also focusing on the next generation of PrEP because adherence to a daily pill is 
challenging.  Most notably, new modalities of PrEP that do not require daily dosing currently are 
being developed, such as long-acting injectables, vaginal rings and rectal microbicide gels for 
use around the time of sex. 
CDC also is engaging multiple groups with an important role in the implementation of PrEP. HIV 
prevention programs are encouraged to integrate PrEP education into their existing activities.  
Advocates are needed to raise awareness of PrEP among persons at substantial risk of 
acquiring HIV.  Providers can increase awareness and uptake of PrEP, while clinical 
professional associations have a role to educate providers and share experiences on the 
provision of PrEP in the field. 
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Susan Philip, MD, MPH 
Director, Disease Prevention and Control Branch 
Population Health Division, San Francisco Department of Public Health (SFDPH) 
and 
Clinical Assistant Professor of Medicine 
Division of Infectious Diseases, University of California-San Francisco 
Dr. Philip presented an overview of STD prevention in MSM in the era of PrEP and HIV TasP.  
San Francisco can be used as a test case to demonstrate the divergence between HIV and 
STD prevention strategies.  SFDPH surveillance data from 2006 to 2013 showed an increase in 
the number of living HIV cases from 14,441 to 15,867; a decrease in the number of new HIV 
diagnoses from 515 to 332; and a decrease in the number of HIV deaths from 327 to 164.  The 
estimated incidence of new HIV infections has remained fairly stable from 498 in 2007 to 437 in 
2011. 
MSM and MSM-IDUs account for 86% of all new HIV diagnoses in San Francisco, but new HIV 
diagnoses have declined or are fairly stable in MSM and all other risk groups.  Unlike HIV, 
however, STD rates are not declining in MSM.  Compared to other men and women, MSM have 
disproportionately high rates of gonorrhea that have steadily increased since 2009.  MSM also 
account for an overwhelming 90% of early syphilis rates.  Of MSM with syphilis, 60% are HIV-
positive. 
Historical data on gonorrhea cases in San Francisco from 1955 to 2013 showed that behavior 
changes among MSM due to HIV prevention strategies in the 1980s-1990s had a secondary, 
profound impact on reducing gonorrhea rates.  SFDPH utilizes its data reported to the CDC 
National HIV Behavioral Surveillance System (NHBS) to address issues related to discordance 
and disparities between HIV and STD prevention.  NHBS is a time-, location- and sampling-
based survey that is conducted every three years with standardized questionnaires.  Blood 
samples are drawn as well to diagnose and estimate the incidence of HIV. 
NHBS data showed that the prevalence of HIV-positive test results among MSM in San 
Francisco remained fairly stable at 23% from 2004 to 2011.  Estimates of HIV incidence among 
MSM decreased overall during the same time period, but self-reports of HIV positivity markedly 
increased.  Rates of unrecognized HIV infection among MSM dramatically decreased to ~7.5% 
in 2011.  The proportion of HIV-positive MSM in San Francisco who do not know their status is 
estimated to be 6.3%. 
SFDPH’s routine HIV surveillance data currently show that persons are now being tested more 
frequently and have more accurate knowledge of their status than in the past.  Median CD4 
counts at the time of diagnosis among persons with new HIV diagnoses in San Francisco 
increased from 364 in 2007 to 434 in 2011. 
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SFDPH’s recent HIV care indicators show better outcomes than national estimates.  Compared 
to the national estimate of linkage to care of 77%, the proportion of persons in San Francisco 
who were linked to care within 3 months of a new HIV diagnosis increased from 84% in 2010 to 
89% in 2012.  Compared to the national estimate of viral suppression of 25%-28%, the 
proportion of persons in San Francisco who were virally suppressed within 12 months of a new 
HIV diagnosis increased from 56% in 2010 to 68% in 2012. 
SFDPH reviewed its 2007-2011 data to identify trends in CD4 counts at the initiation of ART 
stratified by CD4 counts at the time of diagnosis among persons with new HIV diagnoses.  
Among 1,203 persons who initiated ART, the median CD4 counts remained the same at 91 in 
the <200 group and only slightly increased from 270 to 275 in the 200-350 group.  However, the 
median CD4 counts dramatically increased from 352 to 420 in the 351-500 group and from 531 
to 656 in the >500 group. 
SFDPH’s 2004-2010 data showed that early initiation of ART resulted in a marked decrease in 
the median time in months between HIV diagnosis and virologic suppression among persons 
diagnosed with HIV.  San Francisco used these data to become the first city in 2010 to 
recommend that providers universally offer ART to all patients diagnosed with HIV regardless of 
their CD4 count. 
Despite its tremendous progress over time in linking PLWH to care and increasing viral load 
suppression, SFDPH still has not resolved the disparity between HIV and STD prevention 
because risk behaviors have not changed (e.g., multiple partners, substance abuse and an 
increase in self-reported gonorrhea).  CDC’s inclusion of STD testing in the next NHBS-MSM 
cycle would be extraordinarily useful to states and localities, but SFDPH already has initiated 
efforts to maximize sexual health services for MSM. 
San Francisco is one of three sites that received funding from the National Institute of Allergy 
and Infectious Diseases to conduct an open-label PrEP demonstration project in 600 MSM and 
transgender women.  The demonstration project was launched in September 2012 with several 
focus areas:  PrEP uptake, adherence and persistence; PrEP side effects, toxicities and 
resistance in seroconverters; sexual behaviors; and necessary staff and space for successful 
delivery of PrEP in STD clinics. 
SFDPH has proposed several strategies to respond to the steady increase in STD rates among 
MSM.  First, high-quality, culturally-responsive clinical and disease investigation services (DIS) 
and the provision of sexual health information should be continued.  For example, the “Healthy 
San Francisco Program” was established in 2007 to provide documented and undocumented 
low-income residents with a primary care home. 
The Municipal STD Clinic in San Francisco provides services to ~19,000 patients per year with 
MSM accounting for 48% of all patient visits.  Magnet is a Gay Men’s Health Center in San 
Francisco that has increased its capacity to perform gonorrhea, syphilis and chlamydia testing.  
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These two sites diagnose and report 48% of all primary and secondary syphilis cases in San 
Francisco.  Adverse public health impacts should be carefully considered before STD clinics or 
community-based sexual health services for MSM are eliminated in states and localities. 
Second, resources should be targeted to optimizing screening and clinical management of 
STDs and HIV through clinical providers, including a focus on PwP; collecting accurate data on 
the sexual orientation and gender of sex partners; issuing standing orders for self-collected 
screening; and offering consultation or referral for complex cases. 
Third, MSM should be extensively engaged to discuss their priorities and propose collaborative 
opportunities with public health.  Strategies to achieve this goal include street intercept surveys, 
focus groups, consultation with CDC, academic ethnographers and other social scientists, and a 
Gay Men’s Health Summit.  Fourth, SFDPH has reorganized its Population Health Division to 
support a broader and more holistic sexual health framework that addresses both HIV and 
STDs. 
Stephanie Zaza, MD, MPH, CAPT USPHS 
Director, Division of Adolescent and School Health, NCHHSTP 
Centers for Disease Control and Prevention 
DASH is one of five divisions of NCHHSTP and includes three branches in its organizational 
structure.  The School-Based Surveillance Branch focuses on all aspects of risky adolescent 
behavior and coordinated school health.  The branch achieves this goal with the Youth Risk 
Behavior Surveillance System (YRBS), School Health Profiles, and School Health Policies and 
Practices Study (SHPPS). 
YRBS Coordinators in health departments and state/local education agencies (SEAs/LEAs) 
recently voted to include two critically important sexual minority questions on national and core 
YRBS surveys.  The release of YRBS data in 2015 will include the first nationally representative 
data on self-reported sex-of-sex contacts and sexual orientation of youth. 
The Research Application and Evaluation Branch conducts the following activities:  (1) primary 
and secondary research, research synthesis, and evaluation studies of risk factors, protective 
factors and interventions for adolescent sexual behaviors; (2) development and dissemination of 
practical tools and research-based guidance; and (3) provision of evaluation technical 
assistance (TA) to grantees.  The Program Development and Services Branch oversees the 
DASH grant program, including grants management and TA for grantees. 
DASH is the only CDC program that directly funds SEAs/LEAs rather than health departments.  
DASH’s national leadership and expertise in adolescent school health, strong relationships with 
schools, and relocation to NCHHSTP allow CDC to address the complex epidemic of HIV, 
syphilis and rectal gonorrhea in YMSM, particularly YMSM of color. 
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DASH awarded the 2013-2018 cooperative agreement (CoAg) to SEAs/LEAs to implement 
interventions for HIV and STD prevention in schools and conduct school-based surveillance 
programs.  DASH also funds a small number of non-governmental organizations to provide TA 
to grantees.  The funded SEAs will conduct statewide activities and target intensive TA and 
other efforts to 15 selected LEAs in the state.  The funded LEAs will target activities to 20 
schools in their respective districts.  DHAP allocated additional funding for three LEAs in 
Broward County, FL, Los Angeles and San Francisco to conduct a new initiative focused on 
YMSM. 
The DASH CoAg supports a multi-component program that emphasizes several key risk and 
protective factors for HIV, STD and pregnancy prevention among teens.  These components 
include exemplary sexual health education for all students; targeted programs for youth at 
disproportionate risk; teen friendly school-based or school-linked sexual health services; safe 
and supportive environments that address bullying and harassment and emphasize school 
connectedness and family engagement; and educational attainment. 
Dr. Zaza presented data from two sources to illustrate the role of schools as a venue for HIV 
and STD prevention among youth.  The 2012 SHPPS survey included self-reported data from a 
nationally representative sample of school districts and a census of SEAs.  The 2012 School 
Health Profiles included self-reported data from representative samples of secondary schools in 
each state. 
For HIV/STD prevention education, the percentage of districts that required teaching about HIV 
and STD prevention was fairly high in middle and high schools with a range of ~73% to ~82%.  
During the two years before the 2012 SHPPS survey was conducted, ~88% of states and ~49% 
of districts funded or offered professional development to staff that taught health education on 
HIV prevention.  The high proportion of states (86%) and low proportion of districts (~48%) were 
similar for the professional development of staff that taught health education on STD prevention. 
States reported a wide range of percentages of their secondary schools that provided HIV/STD 
prevention education in the following areas: 
• Percentage of secondary schools that taught 12 key HIV, STD and pregnancy 
prevention topics in a required course during grades 6-8 (range: 11%-5%) 
• Percentage of secondary schools that taught 9 key HIV, STD and pregnancy prevention 
topics in a required course during grades 9-12 (range: 30%-96%) 
• Percentage of secondary schools that taught 4 key topics related to condom use in a 
required course during grades 9-12 (range: 0%-85%) 
• Percentage of secondary schools in which the lead health education teacher received 
professional development on 6 key HIV prevention topics during the 2 years before the 
School Health Profiles survey were conducted (range: 4%-33%) 
 
Meeting Minutes: CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment 
May 21-22, 2014 ♦ Page 32 
 
The percentage of school districts that adopted practices or policies on sexual health services 
was extremely low. 
Percentage of Districts 
Policy or Practice HIV STD 
Adopted a policy for schools to provide HIV counseling, testing and 
referral or STD identification, treatment or referral 
15.0% 15.2% 
Adopted a policy for schools to provide HIV or STD prevention in one-
on-one or small-group sessions 
39.5% 36.7% 
Adopted a policy for middle or high schools to make condoms available 
to students 
1.9% 
Had arrangements with any organization or healthcare professional to 
provide HIV or STD prevention at other sites not on school property 
7.4% 7.6% 
Adopted a policy for schools to provide services specifically for gay, 
lesbian or bisexual students 
9.3% 
The percentage of districts that funded or offered HIV professional development to school 
nurses dramatically declined from 2000 to 2012:  from ~45% to ~25% for HIV prevention and 
from 25% to ~14% for HIV counseling, testing and referral.  Striking disparities were reported 
between the percentage of states and districts that provided or offered STD professional 
development to school nurses during the 2 years before the release of the 2012 SHPPS survey:  
64% of states versus ~18% of districts for STD identification, treatment or referral and ~73% of 
states versus ~25% for STD prevention. 
States reported extremely low percentages of their secondary schools that provided students 
with direct access or referrals to healthcare providers for 7 sexual health services.  However, 
states reported a higher percentage of their secondary schools that taught students to access 
valid and reliable health information, products or services related to HIV, other STDs and 
pregnancy in a required course. 
For safe and supportive environments, states reported an extremely low percentage (median 
<25%) of their secondary schools with a Gay/Straight Alliance or similar club.  A similarly low 
percentage was reported for secondary schools in which families and/or community members of 
students helped to develop or implement HIV, STD or teen pregnancy prevention policies and 
programs.  Across states, the median percentage of secondary schools that provided curricula 
or supplementary materials and engaged in 5 practices related to LGBT/questioning youth was 
<25%: 
1. Identify safe spaces for LGBT youth to receive support from administrators, teachers or 
other school staff 
2. Prohibit harassment based on a student’s perceived or actual sexual orientation or 
gender identity 
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3. Encourage staff to attend professional development on safe and supportive school 
environments for all students regardless of their sexual orientation or gender identity 
4. Facilitate access to providers outside of school property who have experience in 
providing health services, including HIV/STD testing and counseling, to LGBT youth 
5. Facilitate access to providers outside of school property who have experience in 
providing social and psychological services to LGBT youth 
CHAC discussed the following topics with the panel on innovative HIV and STD prevention 
approaches that are being implemented for MSM and other at-risk LGBT populations. 
• The need to correct inaccurate data in the Rawlings study that reported emergency 
medicine physicians accounted for only 14% of PrEP prescriptions. 
• The decision-making process, expertise and evidence involved in addressing the use of 
PrEP during pregnancy in the guidelines without supporting data from clinical trials. 
• The need to provide HIV prevention programs with better STD facility- and community-
level screening data. 
• The small sample size and limited data that did not allow transgender persons to be 
specifically addressed in the PrEP guidelines. 
• Concerns regarding the absence of CDC-funded SEAs in Alabama, Georgia and South 
Carolina due to the high burden of HIV and STD morbidity in these states. 
• The lack of communication, minimal coordination and overall disconnect between funded 
SEAs and health departments despite the CDC CoAg requirement for these two entities 
to enter into a formal, written memorandum of understanding. 
• Efforts to minimize stigma associated with teaching topics related to condom use in high 
schools. 
• The possibility of forming a new high-level federal task force led by HHS and the U.S. 
Department of Education to fully integrate health and education. 
• The possibility of school districts implementing a peer-based model in which educators 
with optimal performance in teaching HIV/STD prevention topics in schools would share 
their experiences and lessons learned with peers. 
The discussion resulted in CHAC responding to some of the questions posed by the panel and 
providing specific guidance to CDC on PrEP implementation. 
Responses to the Panel Questions 
• Question 1:  CDC should coordinate its efforts with innovative, non-traditional social 
engagement networks and other initiatives to better identify and reach the high-risk 
population of MSM that currently is not accessing HIV prevention and treatment 
services.  For example, CDC should sponsor a series of listening sessions with MSM in 
informal settings.  If CDC solicits input in non-traditional settings that are comfortable 
and familiar to MSM (e.g., outside of government-sponsored meetings and surveys), 
more accurate self-reported information likely will be provided on the MSM population in 
greatest need of PrEP. 
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• Question 2:  STD clinics are the optimal setting for providing PrEP to MSM.  CDC should 
advise STD clinics to prescribe PrEP to all MSM who receive a positive STD test result 
due to their higher risk of acquiring HIV.  Expanded roles of STD clinics should be to 
screen, offer treatment or provide referrals for both IDUs/non-IDUs and promote HCV 
testing of MSM due to the increase in sexually-transmitted HCV infections in this group.  
However, CHAC acknowledged the challenge in implementing this recommendation due 
to the severe reduction or entire elimination of STD clinics in several states. 
• Question 3:  Creative strategies will be needed to assure uptake of PrEP among eligible 
MSM in primary care settings. 
o A network of local PrEP referral services should be established because PCPs with 
no history of prescribing ARV drugs will not be comfortable in prescribing Truvada® 
for eligible MSM.  In this model, PCPs would document the risk and HIV status of 
MSM and then refer these patients to local providers in the PrEP referral network. 
o The successful Project ECHO® model for HCV should be replicated for the provision 
of PrEP to eligible MSM.  With this approach, each primary care practice would 
designate a physician or nurse as the “PrEP expert.”  The success of Project 
ECHO® as a TA, training and knowledge transfer network, particularly its innovation 
in tele-health, also should be adapted for the provision of PrEP. 
• Question 5:  Numerous training activities, TA modules and other resources to change 
provider behaviors and practices related to screening have been unsuccessful overall.  
As a result, more emphasis should be placed on the current model of STD self-testing.  
Clients can visit an HIV/STD clinic at any time without an appointment to provide urine 
and take their rectal and throat swabs using poster instructions in a bathroom.  Clients 
are then given instructions on obtaining a syphilis serology from the laboratory. 
• Question 6:  Professional development of health education teachers and school nurses 
will not be sufficient to increase HIV/STD prevention and sexual health education in 
schools due to limited funding.  Instead, schools should identify respected and credible 
external champions who have solid relationships and a history of collaboration with 
schools and communities to galvanize support for teaching these topics in schools.  
Examples of external champions include former school gym teachers, coaches and 
guidance counselors, LGBT organizations, and local partners. 
PrEP Implementation 
• PrEP implementation activities should convey messages to the public that strongly 
emphasize the need for continued use of condoms.  Based on SFPHD surveillance data, 
for example, HIV rates in MSM likely will continue to decline with ART, TasP and PrEP, 
but STD rates in this group will continue to steadily increase because condom-less sex, 
multiple partners and other risk behaviors have not changed.  The CDC guidelines 
clearly state that PrEP does not protect against other STDs and condom use can 
increase the efficacy of PrEP.  However, these messages should be widely publicized in 
other formats for communities and laypersons who will not read the guidelines.  
Moreover, condom use messages will be particularly important for YMSM <18 years of 
age because PrEP most likely will not be a practical or feasible option for this population. 
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• Poverty and no insurance coverage are the top two risk factors that deter HIV prevention 
and treatment, but the employed and insured “worried well” population likely will account 
for the greatest uptake of PrEP.  The following actions should be taken during PrEP 
implementation to address this issue. 
o CDC should urge all groups with a role in PrEP implementation (e.g., HIV prevention 
programs, providers, advocates and national organizations) to widely publicize the 
availability of programs that will offer PrEP to low-income and uninsured persons at 
no charge. 
o The four groups CDC has identified for PrEP implementation will play an important 
role, but these traditional partners will not substantially increase access to HIV 
prevention and treatment services for populations at highest risk.  As a result, ACA 
enrollment and PrEP implementation activities should simultaneously occur in non-
traditional settings with primarily poor and uninsured populations:  (1) state/local 
programs serving General Assistance recipients and new applicants; (2) programs 
serving adults and adolescents recently released from correctional institutions, 
including the juvenile justice system; and (3) programs serving homeless persons, 
including homeless adolescent sex workers.  Coordinated efforts with non-traditional 
programs will strengthen the ability of PrEP to serve as a broad public health 
intervention and better control the HIV epidemic.   
• Providers should be given clear guidance on limiting each prescription of PrEP to a one-
month supply.  The need to refill prescriptions each month will greatly increase patient/ 
provider interactions.  Providers can use the monthly visits as an opportunity to routinely 
conduct HIV testing and discuss risk behaviors with their patients, particularly MSM. 
• The CDC guidelines include several tools that will be extremely helpful to providers in 
implementing PrEP in clinical practice.  However, the implementation activities also 
should include model guidance on adapting the PrEP tools for individual clinical settings 
and local needs. 
Panel Presentation: HIV and HCV Among IDUs and the 
Prescription Drug Overdose Epidemic 
A panel of CDC representatives presented data to illustrate drug user health in the context of 
HIV and HCV among IDUs and the prescription drug overdose epidemic.  The presentations are 
set forth below. 
Advice Requested from CHAC by CDC and HRSA:  
1. What steps can CDC and HRSA take to more holistically and better address drug user 
health issues? 
2. What strategies can CDC implement to better integrate its activities for the drug user 
population (e.g., HIV, HCV and prescription drug overdose)? 
3. What steps can CDC and HRSA take to increase collaboration with other federal agencies, 
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particularly the Substance Abuse and Mental Health Administration (SAMHSA), National 
Institute on Drug Abuse, and the White House Office of National Drug Control Policy? 
4. What steps can CDC and HRSA take to support health departments and providers in 
offering integrated services for drug users? 
5. What steps can CDC and HRSA take to leverage ACA-related changes in healthcare 
coverage to improve access to and quality of prevention, care and treatment services? 
Amy Lansky, PhD, MPH 
Deputy Director for Surveillance, Epidemiology and Laboratory Sciences 
Division of HIV/AIDS Prevention, NCHHSTP 
Centers for Disease Control and Prevention 
Dr. Lansky presented data on HIV infection among persons who inject drugs and described 
CDC’s prevention strategies for this population.  CDC surveillance data showed a peak in AIDS 
diagnoses among IDUs in the mid-1990s, and has continued to decrease over time.  In 2011, 
male, female and MSM IDUs accounted for 11% of HIV diagnoses.  The percentage of IDU-
related cases that were male injection drug users generally increased with increasing age, while 
the percentage of diagnoses that were males with HIV infection attributed to male-to-male 
sexual contact and injection drug use increased with increasing age until the 20-24 age group, 
for which percentages then decreased with increasing age until the 20-24 age group, for which 
percentages then decreased with increasing age.  African American IDUs accounted for the 
majority of new HIV diagnoses among IDUs in the Northeast, Midwest and South, but disparities 
also were observed between white and Hispanic IDUs.  Meta-analysis combined data from four 
national surveys to estimate the proportion of persons >13 years of age in the United States 
with any IDU history and found that persons who inject drugs comprised 2.6% of the US 
population (approximately 6.6 million persons). 
CDC gathers data through the National HIV Behavioral Surveillance System (NHBS) on MSM, 
IDUs and heterosexuals at increased risk of HIV infection each year on a rotational basis (or 
data collection for each group every three years).  NHBS monitors the prevalence and trends in 
HIV-related behaviors (e.g., sex and drug use), HIV testing, HIV infection, and use of prevention 
services. The second NHBS-IDU cycle in 2009 captured data on 10,090 IDUs in 20 cities. Key 
findings from this dataset are highlighted below. 
The percentage of IDUs who engaged in HIV-associated behaviors was high: engaged in 
condomless vaginal sex (64%), had multiple sex partners (46%), shared syringes (34%), shared 
other injection drug equipment (58%).  The proportion receiving HIV testing in the past year 
(49%), and who participated in behavioral interventions (19%) was fairly low. 
The prevalence of HIV infection among persons in NHBS-IDU was 9%. By age, the HIV 
prevalence was 4% in younger IDUs 18-29 years of age and ~10% in older IDUs >30 years of 
age.  Compared to older IDUs, younger IDUs were at higher risk for receptive syringe sharing 
based on several independent factors:  binge drinking in the past 30 days, daily IDU in the past 
 
Meeting Minutes: CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment 
May 21-22, 2014 ♦ Page 37 
 
12 months, attainment of syringes from unreliable sources in the past 12 months, and 
unprotected sex in the past 12 months.  These data from NHBS-IDU demonstrate the need to 
consider younger IDUs as a new generation of an at-risk HIV population.  Younger IDUs have a 
lower HIV prevalence, but their sexual and IDU behaviors greatly increase the risk of HIV 
infection.  Continued efforts are needed to strengthen and target HIV prevention activities to 
young IDUs. 
CDC has implemented a number of HIV prevention strategies for IDUs.  Guidelines were 
published in the MMWR in November 2012 on integrated prevention services for HIV, viral 
hepatitis, STDs and TB for IDUs.  The guidelines recommended specific public health strategies 
for this population:  substance use prevention and treatment, outreach programs, drug use and 
infectious disease risk assessments, screening and diagnosis for infections, vaccination, 
prevention of mother-to-child transmission, risk reduction interventions, partner services, 
referrals and linkage to care, treatment for infectious diseases, and integrated services. 
In addition to implementing these strategies, CDC also produces fact sheets on topics that are 
relevant to the U.S. IDU population, such as HIV/substance use and HIV risk among adult sex 
workers.  The CDC.gov/idu website was archived in 2005, but plans are underway to revise and 
update this resource later in 2014.  CDC reviewed its existing evidence-based interventions to 
determine those that would be the most cost-effective, high-impact, relevant and scalable—
while only one has a specific component for IDUs (Community Promise), others would be 
relevant for IDUs who are HIV-positive, MSM, or female. 
CDC’s 2014 PrEP guidelines recommend PrEP for HIV-uninfected persons who had injected 
illicit drugs within the past 6 months and shared equipment or had been in drug treatment within 
the past 6 months.  The guidelines emphasize that the FDA labeling indication for Truvada® as 
PrEP is only for preventing sexual transmission, but many IDUs also meet these criteria. 
Jon Zibbell, PhD 
Health Scientist & Medical Anthropologist 
Division of Viral Hepatitis, NCHHSTP 
Centers for Disease Control and Prevention 
Dr. Zibbell presented national data on HCV infection among persons who inject drugs (PWID).  
In the general population, 4.1 million persons are HCV antibody-infected, with 75% living with 
chronic infection (3.2 million) and 45%-85% unaware of their infection.  HCV is the most 
common bloodborne infection in the United States and is the leading cause of liver transplants 
and liver cancer.  Hepatocellular carcinoma is the fastest rising cause of cancer-related deaths 
with HCV-related deaths doubling to >17,000 per year in 1999-2007. 
Liver disease is the second leading cause of death for PLWH/AIDS and HIV hastens the 
progression of HCV-related liver disease.  HCV prevalence is 5.3 times higher in persons born 
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between 1945-1965 (3.29%) compared to other age groups (0.55%), and this age cohort 
accounts for 81% of adult chronic HCV infections and 73% of HCV-associated mortality.   
Injection drug use (IDU) is the principal ‘motor’ of HCV incidence.  HCV antibody prevalence 
among PWID is between 30%-70%, depending on frequency and duration of use, and incidence 
rates among PWID are 16%-42% annually.  Young PWID (18-29 years of age) have lower anti-
HCV prevalence between 10-30%. Of 4.5 million persons with HIV/HCV co-infection globally, 
the United States accounts for 25% of HIV/HCV co-infection, while China, Vietnam, Ukraine and 
other countries account for 80% of large IDU-related epidemics.  Recent data show that HCV 
mortality (3.2 million HCV-infected persons) now surpasses HIV mortality (1.2 million HIV-
infected persons). 
CDC published its recommended testing sequence for identifying current HCV infection in 2013.    
Because 15%-20% of persons who are exposed to HCV will clear the virus, follow-up RNA 
testing is recommended for persons with an HCV antibody-positive test result to determine 
whether chronic infection is present.  No further action is recommended for persons with a non-
reactive HCV antibody test result who are not engaging in risk behaviors.  Follow-up testing is 
recommended for persons engaging in risk factors.  Linkage to care and treatment are 
recommended if current HCV infection is detected. 
Of 3.2 million persons currently living with chronic HCV in the United States, 50% receive anti-
HCV testing, 38% are linked to care, 23% receive follow-up, HCV RNA testing, 11% are treated, 
and 6% are cured.  In other words, only 6% of the 3.2 million persons chronically infected are 
cured. Advances in all-oral, non-interferon-based agents are expected to greatly improve the 
HCV test, care and cure continuum.  Most notably, SVRs of 96%-98% for HCV genotype 1 have 
been reported with the new drugs. 
Studies are underway to determine the feasibility of replicating HIV Treatment as Prevention 
(TasP) for HCV, particularly to reduce overall incidence and prevalence among PWID.  Martin, 
et al. have modeled the effects of scaling-up of treatment for PWID based on 10-80/1,000 
populations annually and baseline chronic HCV prevalence at 25%, 50% and 65%.  The results 
showed significant reductions in HCV infection among PWID over a span of 15 years. 
CDC published MMWR articles on the increase in new injection-related HCV infections among 
persons <30 years of age reported by Massachusetts, New York State and Wisconsin.  
However, CDC also has received similar reports from 15 additional states.  The demographics 
of HCV incidence have changed since the 1990s.  Males, minorities, urban residents and 
persons 40-49 years of age previously accounted for the majority of anti-HCV prevalence.  
Current HCV cases primarily involve males and females equally, predominantly white persons, 
non-urban, suburban or rural residents, and young PWID 18-29 years of age, many of whom 
report antecedent prescription opioid analgesics (POA) misuse. 
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States reporting significant increases in HCV infections among young persons were virtually the 
same as those with the largest amount of opioid analgesics prescribed per 10,000 persons:  
Alabama, Arkansas, Florida, Kentucky, Oklahoma, Oregon, Tennessee, Virginia, Washington 
and West Virginia.  CDC recently investigated and published results of an HCV cluster outbreak 
among young persons in New York State (Zibbell et al 2014, American Journal of Public Health, 
in press).  Young persons who reported injecting POA only were 5 times more likely to be HCV-
infected than those who inject drugs other than POA.  Similar results were reported in two 
additional papers (Havens 2012; Bruneau 2011).  Kentucky reported an increase in poly-drug 
overdoses among young persons that included a mixture of opioids, benzodiazepines and other 
drugs.  
In response to this emerging epidemic, states are implementing stricter prescribing policies to 
reduce the availability of prescription opioids.  Based on Washington State’s experience, 
however, enforcement of a more stringent prescription opioid policy can lead to unintended 
consequence such as increased heroin use. 
Traditional HIV prevention strategies with proven success among PWID have not been as 
effective in their replication for HCV prevention among this population.  However, several 
studies in the literature have reported reductions in HCV of up to 80% among PWID with a 
combination of readily available, low-threshold opioid agonist therapy (e.g., methadone and/or 
buprenorphine) and Syringe Access Programs.  These combination prevention strategies were 
found to reduce the overall HCV/HIV incidence and risky injection behaviors (e.g. injection 
equipment sharing) among PWID. 
Brian Manns, PharmD 
Pharmacist 
National Center for Injury Prevention and Control 
Centers for Disease Control and Prevention 
Dr. Manns presented national data to illustrate the prescription drug overdose epidemic.  
Prescription drug overdose deaths have nearly quadrupled from 1999 to 2010.  Prior research 
has suggested methadone accounts for the vast majority of these deaths.  Of ~30,000 
unintentional drug overdose deaths in 2010, 16,651 involved prescription opioid pain relievers.  
Dual use of prescription opiates and benzodiazepines accounted for 75% of these deaths. 
Each opioid overdose death in 2010 was associated with 15 admissions to substance abuse 
treatment facilities, 26 emergency department visits, 115 persons who reported substance 
abuse or dependence, and 733 non-medical users.  Persons 45-49 are at highest risk of drug 
overdose deaths.  The rise in opioid deaths has paralleled the increase in opioid sales and 
admissions to substance abuse treatment facilities. 
At the state level, Utah collected data on the characteristics of 254 unintentional opioid pain 
reliever overdose deaths that occurred in 2008-2009:  history of pain (~89%), history of 
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hospitalization for substance abuse (~80%), history of illicit drug use (~61%), mental illness 
diagnosed by a provider (~56%), and use of an opioid pain reliever for reasons other than pain 
(~30%). 
At the national level, the National Survey on Drug Use and Health reported ~12 million non-
medical users of prescription opioids in 2012.  A steady rise in heroin abuse and dependence 
has been observed with the increase in opioid sales and overdose deaths.  Increased heroin 
use is perhaps a consequence of the prescription opioid epidemic.  Heroin use and misuse of 
prescription opioids in the past year were reported in 7 out of 10 persons.  Among dual users of 
both heroin and prescription opioids in the past year, misuse of prescription opioids occurred 
first in 3 out of 4 persons. 
CDC is implementing a three-prong approach at the state level to address the prescription drug 
overdose epidemic nationally.  First, the quality of data is being improved to better protect public 
health.  Trends are being tracked to monitor the epidemic.  For example, CDC-funded states 
have launched Prescription Drug Monitoring Programs to determine the frequency in which 
prescriptions are written, identify specific locations that fill prescriptions, and communicate with 
other states regarding prescribing and dispensing patterns. 
Second, state efforts are being supported to customize and target prevention resources.  For 
example, North Carolina launched Project Lazarus as a community-based overdose prevention 
and opioid safety initiative.  Third, healthcare providers are given data, tools and guidance to 
enhance patient safety, inform evidence-based decision-making and improve population health.  
For example, state Prescription Drug Monitoring Programs are being integrated into EHRs. 
CHAC discussed the following topics with the panel on drug user health in the context of HIV 
and HCV. 
• New activities by CDC and its federal partners (e.g., the development and dissemination 
of implementation toolkits, EHR modules and other resources) to increase the capacity 
and confidence of PCPs in treating opiate dependence in primary care settings. 
• The need to incorporate and prioritize drug user health and other public health issues 
into CMS ACOs. 
• The need to create new policies and provide education at both physician and community 
levels to broadly improve drug user health nationally. 
Preparation for the CHAC Business Session 
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Jeanne Marrazzo, MD, MPH, CHAC co-Chair 
Professor of Medicine, Harborview Medical Center 
University of Washington 
Dr. Marrazzo moderated a discussion for CHAC to consider issues from the updates and panel 
presentations on day 1 that would warrant formal action during the Business Session on the 
following day.  She noted that the meeting packets included a guidance document to assist the 
CHAC members in drafting resolutions and recommendations. 
 
Champions 
 
Topic 
 
Basis for Resolution/Recommendation 
 
Dr. Steven Johnson (Lead) 
Dr. Sanjeev Arora 
Dr. Virginia Caine 
Mr. Guillermo Chacon 
Dr. Britt Rios-Ellis 
HIV/HCV Testing • CHAC endorses the importance of 
performance measures for HIV and HCV 
testing. 
• CHAC recommends that HIV and HCV 
testing be given higher priority in ACOs 
and the healthcare system through 
Meaningful Use indicators or performance 
measures. 
• CHAC recommends that CDC and HRSA 
explore strategies to expedite the process 
of integrating performance measures for 
HIV and HCV testing into EHR systems. 
• CHAC recognizes the relevance of clinical 
decision tools and emphasizes the need to 
increase the linkage between HIV/HCV 
screening and care. 
Mr. Guillermo Chacon (Lead) 
Dr. Elinore McCance-Katz 
Prescription Drug 
Overdose 
Epidemic 
• CHAC is extremely concerned about the 
alarming epidemic of prescription opioid 
and heroin overdoses that has emerged in 
the United States. 
• CHAC calls for a proactive response to 
this crisis to prevent exposure to other 
diseases (e.g., HIV and HCV) in 
vulnerable populations. 
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Champions 
 
Topic 
 
Basis for Resolution/Recommendation 
 
Dr. Sanjeev Arora-Lead 
Dr. Bruce Agins 
Dr. Kathleen Clanon 
Dr. Jeanne Marrazzo 
National HCV 
Program 
• CHAC recommends support for an 
external evaluation to be conducted to 
determine the cost of establishing a robust 
National HCV Program. 
• If funding is not sufficient to support a 
National HCV Program, CHAC 
recommends that HRSA encourage all 
Federally Qualified Health Centers 
(FQHCs) to incorporate an electronic 
reminder into EHRs to conduct HCV 
screening of the 1945-1965 birth cohort. 
• CHAC recommends that a legislative 
review be conducted of existing statutes to 
identify areas in which CDC and HRSA 
can enhance collaboration to improve 
HCV screening, treatment and care. 
• CHAC recommends that CDC and HRSA 
provide their funded SHDs/LHDs with 
clear guidance on federal expectations 
regarding HCV screening and treatment. 
• CHAC supports the reestablishment of its 
Viral Hepatitis Workgroup to closely work 
with CDC and HRSA on addressing all 
issues in the HCV resolution. 
Dr. Kathleen Clanon (Lead) 
Ms. Angelique Croasdale 
Adolescent 
Health 
• CHAC recommends that CDC issue 
formal guidelines for SBHCs and school 
nurses to implement the 7 EBIs for sexual 
health services to all youth, including 
LGBT youth and YMSM.   
Dr. Jeanne Marrazzo PrEP 
Implementation 
• CHAC recognizes the significance and 
value of the PrEP Guidelines due to their 
high level of detail and quality for 
clinicians. 
• CHAC welcomes and supports 
subsequent activities and data to 
understand challenges to implementation 
and targeting of PrEP to populations in 
most need. 
• CHAC recommends that CDC and HRSA 
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Champions 
 
Topic 
 
Basis for Resolution/Recommendation 
 
require their grantees to “vigorously 
pursue” the use of PrEP in appropriate 
populations, including groups in most 
need of HCV screening and treatment. 
• CHAC recommends that CDC present 
regular updates on results of the PrEP 
demonstration projects to facilitate its 
ongoing assessment on implementation. 
Public Comment Session 
Carole Treston, RN, MPH 
Chief Nursing Officer 
Association of Nurses in AIDS Care (ANAC) 
Ms. Treston made the following comments for CHAC’s consideration.  ANAC recently released 
a position statement and soon will issue a letter to The New York Times to support CDC’s PrEP 
Guidelines in general and emphasize the important role of nurses in implementation of PrEP in 
particular. 
ANAC has proposed a collaborative project with State Nurses Associations and nursing 
departments in large hospital systems in three cities to provide continuing education on HCV 
care.  If funded, the project will strengthen the capacity of the nursing workforce overall, more 
extensively engage nurses in HCV testing, reduce stigma related to HCV in primary care 
settings, and encourage HIV/AIDS nurses to provide more holistic care in HCV and other areas. 
Ms. Treston advised CHAC to emphasize the important role of nurses in its guidance to CDC 
and HRSA on implementation of prevention and treatment activities.  CHAC also should ensure 
that nurses are represented on its workgroups and teleconferences to discuss these issues.  
Most notably, nurses ultimately will be responsible for implementing expanded HCV screening 
and treatment guidelines in the field and providing ongoing counseling and support to PrEP 
patients. 
Carl Schmid 
Deputy Executive Director 
The AIDS Institute (TAI) 
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Mr. Schmid made the following comments for CHAC’s consideration.  TAI identified several new 
opportunities for reimbursement of HCV testing.  The new USPSTF Grade B recommendation 
will impact coverage for HCV screening by private insurers, Medicaid and Medicare as a result 
of ACA.  Beginning in June 2014, Medicaid expansion states and private insurance plans both 
inside and outside of Health Insurance Marketplaces must cover HCV testing for high-risk 
individuals and the 1945-1965 birth cohort. 
The decision to cover HCV testing in non-Medicaid expansion states will remain at the 
discretion of the individual state.  For example, California, New York and Texas cover routine 
HCV screening, while Florida covers medically necessary HCV testing.  CMS will soon finalize 
Medicare coverage determinations for HCV screening to assure consistency with the USPSTF 
Grade B recommendation.  To provide the public with detailed information on these new 
opportunities, TAI recently released a coverage guide for HCV screening in conjunction with 
National Hepatitis Testing Day on May 19, 2014. 
TAI recognizes that tremendous progress has been made in policy development for coverage of 
HIV and HCV preventive services, but existing gaps still need to be addressed in Medicaid 
coverage at the state level and Medicare coverage of routine HIV testing.  These policies must 
now be widely implemented to cover HIV and HCV testing as billable services.  TAI is pleased 
that additional resources were allocated in CDC’s FY2014 and FY2015 budgets to expand HIV 
and HCV preventive services.  These funds will dramatically increase testing and link more 
persons to care. 
With no further discussion or business brought before CHAC, Dr. Cheever recessed the 
meeting at 4:54 p.m. on May 21, 2014. 
Opening Session: May 22, 2014 
Jeanne Marrazzo, MD, MPH, CHAC co-Chair 
Professor of Medicine, Harborview Medical Center 
University of Washington 
Dr. Marrazzo conducted a roll call to determine the CHAC voting members, ex-officio members 
and liaison representatives who were attending the meeting either in person or remotely.  None 
of the CHAC voting members publicly disclosed any individual or institutional conflicts of interest 
for the record that were new or different than those declared on day 1 of the meeting. 
Dr. Marrazzo confirmed that the voting members and ex-officio members in attendance 
constituted a quorum for CHAC to conduct its business on May 22, 2014.  She called the 
proceedings to order at 8:32 a.m. and welcomed the participants to day 2 of the CHAC meeting. 
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Dr. Marrazzo reviewed the day 2 agenda and highlighted six recommendations/resolutions that 
would be proposed during the Business Session for CHAC’s consideration, deliberation and 
formal vote.  However, she clarified that the CHAC members were free to propose additional 
recommendations/resolutions based on the day 2 presentations. 
Dr. Bruce Agins, a CHAC member, commended Dr. Cheever for her outstanding efforts in 
formally engaging CMS in CHAC’s deliberations.  He noted that the expertise and input by Drs. 
Stephen Cha and Richard Wild, the primary and alternate ex-officio members for CMS, have 
been particularly helpful for CHAC to provide more informed guidance to CDC and HRSA on 
ACA-related issues. 
Update by the CHAC Integration Workgroup 
Bruce Agins, MD, MPH 
Medical Director, AIDS Institute 
New York State Department of Health 
CHAC Member & Workgroup co-Chair 
Kali Lindsey 
Deputy Director, Public Policy 
amfAR, The Foundation for AIDS Research 
CHAC Member & Workgroup co-Chair 
William Garrett 
Program Associate, AIDS Institute 
New York State Department of Health 
The workgroup covered the following topics in the update on its recent activities.  The 
workgroup extensively discussed the tremendous variation among groups in their use, meaning 
and interpretation of “integration.”  As a result, the workgroup acknowledged the need to clearly 
define “integration” for CHAC’s purposes. 
In response to CHAC’s previous advice, the workgroup developed a new “Integration Matrix” to 
illustrate various types of service integration.  The matrix will be regularly updated to serve as a 
living document in two major areas:  (1) a repository of evidence and detailed information on 
specific types of integration and (2) a resource from which to extract common themes, describe 
challenges, and identify potential integration opportunities.  
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INTEGRATION MATRIX 
Integration Types: 
• Disease-specific integration: HIV, HCV, STDs, Mental Health, Substance Abuse [purple boxes] 
• Integration in primary care: CHCs/FQHCs, PCMHs [blue boxes] 
• Integration of public health with medicine [green boxes] 
 
Matrix Key:  
Axes = Services 
X axis: Integration of _____ 
Y axis: Integration into _____ 
 
Relevant information in each link: 
• Facility type with integrated services 
• Research and policy papers 
• Funding opportunities  
 
  Infectious Diseases (Clinical) Primary 
Care  
ID 
(PH) 
Behavioral Health Women'
s 
Health 
Family 
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g   HIV 
V
H 
STD
s 
T
B 
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Health 
Substance 
Abuse 
Infectious  
Diseases 
(Clinical) 
HIV 
        
HIV into 
PC 
    HIV into 
Substance Abuse 
    
Viral 
Hepatitis 
Hepatitis 
into HIV 
 
      
Viral 
Hepatitis 
into PC 
    Viral Hepatitis into 
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STDs 
STDs into 
HIV 
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Substance 
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TB 
TB into 
HIV 
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PC 
    TB into 
Substance 
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Primary Care  
Primary 
Care into 
HIV 
 
   
  
  
    Primary Care into Behavioral Health  
    
 
Infectious Diseases 
(Public Health) 
Public 
Health 
into HIV 
 
ID PH into 
PC 
 
PCS
I 
  Public Health 
Into Substance 
Abuse 
    
Behaviora
l 
Health 
Mental 
Health 
Mental 
Health 
into HIV 
Mental health 
into non- 
HIV clinical 
Infectious  
Diseases   
Behaviora
l Health 
into PC 
    Mental Health 
Into Substance 
Abuse 
    
Substanc
e 
Abuse 
Substanc
e Abuse 
into HIV 
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  Infectious Diseases (Clinical) Primary 
Care  
ID 
(PH) 
Behavioral Health Women'
s 
Health 
Family 
Plannin
g   HIV 
V
H 
STD
s 
T
B 
Mental 
Health 
Substance 
Abuse 
Women's Health 
Women's 
Health 
into HIV 
  
Women's 
Health 
into PC 
      
    
Family Planning 
Family 
Planning 
into HIV 
  
Family 
Planning 
into PC 
      
    
 
The workgroup conducted an exhaustive literature review to identify and compile federal and 
national evidence-based integration guidance, policies and initiatives in an inventory to support 
the Integration Matrix. 
 
Source Resource 
 
REPORTS AND GUIDANCE ON INTEGRATION 
IOM “Primary Care and Public Health: Exploring Integration to 
Improve Population Health,” 2012 
CDC “Prevention of HIV/AIDS, Viral Hepatitis, STDs, and TB 
Through Health Care,” 2014 
www.cdc.gov/nchhstp/PreventionThroughHealthCare 
CDC, de Beaumont Foundation, 
Duke University Department of 
Community and Family Medicine 
“Public Health and Primary Care Together: A Practical 
Playbook,” 2013, https://practicalplaybook.org 
HRSA “Public Health: Five Priorities,” 2012 
www.hrsa.gov/publichealth 
CDC, NACHC, Association of State 
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Source Resource 
 
NATIONAL INTEGRATION POLICIES AND INITIATIVES 
CDC PCSI Initiative 
SAMHSA & HRSA SAMHSA-HRSA Center for Integrated Health Solutions 
(behavioral health and primary care) 
HRSA & U.S. Department of 
Veterans Affairs 
Reports from RWHAP and VA Hospitals on lessons 
learned from integrated models 
The AHRQ Academy Integrating Behavioral Health and Primary Care 
NASTAD Integration of HCV into HIV guidance; exploration of HIV/ 
HCV in CHC/health department collaborations 
NACHC Quality of HIV, HCV, behavioral health, sexual health and 
LGBT health in CHCs and the clinical workforce 
The workgroup is using the Integration Matrix and inventory of integration resources as the 
bases to determine its next steps.  However, the workgroup welcomes CHAC’s advice in two 
areas to further refine its future direction. 
Questions 1a/1b:  What should be CHAC’s specific areas of focus in terms of integration?  What 
strategies should be implemented for integration to occur?  To address questions 1a/1b, the 
workgroup abstracted common implementation strategies across the three major types of 
integration:  disease-specific integration, integration in primary care, and integration of public 
health with medicine.  The workgroup will apply findings from questions 1a/1b to advise CHAC 
on providing CDC and HRSA with informed guidance on integrated care and services. 
The workgroup agreed that 7 integration components would be needed to address questions 
1a/1b.  Integration component 1 is a teamwork approach with a collaborative, multidisciplinary 
medical team.  The composition of the medical team should reflect the clinical needs of the 
patient population.  Formal partnership agreements should be established to clearly delineate 
the core roles and responsibilities of all medical team members.  The medical team should 
include a combination of the following types of providers: 
• PCPs 
• Nurses 
• Behavioral health providers (e.g., psychologists, psychiatrists and substance abuse 
counselors) 
• Infectious disease practitioners (e.g., HIV, HCV and STD providers) 
• Health department partners 
• Social workers 
• Community health workers 
• Care coordinators, care managers and patient navigators 
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Integration component 2 is a strong workforce with enhanced capacity for HIV, other infectious 
diseases and behavioral health.  Access to expertise should be increased to improve the 
competency of providers and promote the delivery of evidence-based treatment in primary care 
settings.  Task-shifting should be considered as an option in building the integration workforce. 
Integration component 3 is strong leadership that will create and institutionalize a culture of 
integration, leverage resources to support integration, and articulate a vision and goal to 
improve integration outcomes.  Integration component 4 is models of service integration that will 
provide co-located services, a full continuum of services within the medical team, virtual onsite 
coaching with access to expertise to for capacity building, and a consultation network. 
Integration component 5 is resources that will pay for all services within an integrated system of 
care; leverage joint resources to achieve patient-centered goals in primary care, behavioral 
health and other settings; and offer reimbursement options for primary care and behavioral 
health reported in the literature: 
• Fully capitated payment (e.g., an established amount per enrolled person) 
• Case-rate payment (e.g., reimbursement based on the expected cost for clinically-
defined episodes of care) that would augment fee-for-service payments 
• Fee-for-service 
• Pay-for-performance 
• Shared savings models 
Integration component 6 is information systems that will be designed to perform the following 
functions:  capture and report data related to integrated models of care, consolidate EHR data, 
provide clinical decision support tools, maintain registries, collect longitudinal data, use public 
health data to inform clinical priorities and decision-making, and share data platforms (e.g., 
Health Information Exchanges and Regional Health Information Organizations). 
Integration component 7 is the application and use of data to achieve three major outcomes.  
Internal assessments of the quality of care will be performed to ensure the provision of 
evidence-based treatment, measure clinical outcomes, and solicit patient experiences to inform 
QI.  Provider- and program-level outcomes will be examined on a routine basis.  Integrated 
models will be evaluated to make a business case for this effort. 
The workgroup identified several challenges to implementing the 7 integration components:  
limited resources; inadequate workforce capacity; insufficient evidence (particularly in primary 
care settings); competing priorities; minimal support to build competency; bureaucratic silos and 
standalone academic divisions; the absence of available leadership; and lack of information 
systems to capture integrated services. 
Question 2:  What are best approaches for CHAC to formulate specific recommendations to 
support service integration utilizing the 7 integration components?  The workgroup’s next steps 
will be to focus on addressing this question. 
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CHAC made several suggestions in response to the workgroup’s request for input on its next 
steps and future direction. 
• Emphasis should be placed on developing indicators to measure integration. 
• Additional models should be included in the Integration Matrix. 
o Integrated public health surveillance systems are extremely beneficial in targeting 
resources due to their capacity to identify gaps in service delivery for certain 
populations in specific geographic areas. 
o Project ECHO® has been enormously successful in integrating outreach and TA for 
HCV. 
• CHAC’s focus should be directed to three important components in the Integration 
Matrix:  HIV, viral hepatitis and STDs into primary care.  Efforts should be made to 
determine the evidence base for successful integration of prevention and treatment of 
these three infections to support both public health and personal health outcomes in 
primary care settings.  However, other CHAC members emphasized the important need 
to also focus on integrating behavioral health into primary care.  Most notably, the lack of 
trained mental health professionals is one of the top five indicators for poor outcomes in 
substance abuse disorders.  Mental health support also is instrumental in providing HIV 
care. 
• Future research on integrated services should be conducted from the perspective of 
patients.  These findings should be included in any new integration guidance, policies 
and initiatives to ensure that the needs of patients are met. 
• An analysis should be performed to identify federal funding streams, opportunities and 
other resources for integration that would have the highest potential for broad 
implementation at state and local levels.  Most barriers to integration occur in states and 
localities. 
• CHAC’s formal resolution or recommendation on integration should be linked to the 
President’s Executive Order on the HIV Care Continuum Initiative.  This effort focuses 
on the need to improve integration of care and services for PLWH in order to maximize 
the public health impact across the Care Continuum.  A clear linkage between CHAC’s 
formal resolution/recommendation and the President’s Executive Order would play an 
important role in minimizing barriers to integration among state and local providers. 
Panel Presentation: Perspectives from the Field on 
Public Health/Primary Care Integration 
A panel of guest speakers described perspectives from the field regarding state and local 
collaboration to prevent HIV, STDs and viral hepatitis.  The overviews are set forth below. 
Advice Requested from CHAC by the Guest Speakers:  
1. What steps can CHAC take to influence primary care, Medicaid and other systems at state 
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and local levels? 
2. What strategies can CDC implement to raise the profile of infectious disease prevention 
among Medicaid directors, Primary Care Associations (PCAs), and other key providers 
and payers at state and local levels? 
3. What data are needed to demonstrate that HIV, STD and viral hepatitis prevention meet 
the triple aims of healthcare:  improving the care experience, lowering cost and improving 
population health? 
4. What creative models are being utilized?  What actions are needed to compile and share 
these models? 
John Auerbach, MBA 
Distinguished Professor of Practice and Director 
Institute on Urban Health Research and Practice (the Institute) 
Northeastern University 
Mr. Auerbach described ongoing efforts in the field to reexamine the roles of SHDs/LHDs.  CDC 
awarded a grant to the Institute to conduct research to better understand efforts to integrate 
STD public health services into primary care settings due to ACA-related changes and SHD/ 
LHD budget cuts.  The project was designed to identify challenges, opportunities, successes 
and lessons related to integration; determine assistance that would be needed to support future 
integration efforts; and build resources to support this initiative. 
The Institute and its partners initiated the project by conducting interviews in 10 states with 5 
local health directors, 7 state health commissioners, 5 state PCA leaders, and 4 CHC leaders.  
The project sites were selected to reflect national diversity in terms of geographic areas, 
demographics, population density and Medicaid expansion policies.  The project was conducted 
prior to ACA implementation in January 2014. 
Key findings of the research are highlighted as follows.  Public health currently provides a range 
of STD activities (DIS, epidemiology, outbreak response, laboratory services, assurance of 
direct or indirect access to services, and limited primary prevention) some of which are likely to 
continue and others of which may be reduced as health care insurance coverage is expanded.  
In particular there is potential to shift the provision of some direct STD clinical services to 
primary care sites as a result of the ACA.   
Currently public health agencies often offer a limited range of clustered clinical services such as 
ST screening and treatment, TB screening and treatment, reproductive health and Women, 
Infants and Children (WIC) Programs.  Billing was found to be the exception rather than the rule 
in these settings. Public health was found to operate CHCs or FQHCs in limited instances.  
Integration, collaboration and coordination between public health and primary care exist but is 
limited and uneven throughout the country.  However, SHDs/LHDs across the country 
expressed a great deal of interest in advancing integration with primary care where possible. 
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With the implementation of the ACA and the expansion of health insurance coverage, an 
alternative model might replace the current one. It might include the use of DIS and 
epidemiology to assist primary care and the increased likelihood that primary care sites, 
particularly CHCs, would more frequently and regularly treat STDs.   
Challenges and opportunities were identified.  The ACA will continue to change health care in 
America, particularly with the addition of a large newly-insured populations.  At this time, 27 
states (including the District of Columbia) have expanded Medicaid, 19 states chose not to 
expand Medicaid, and 5 states are continuing to debate the issue.  ACA enrollment of large 
uninsured populations in Medicaid expansion states likely will have a significant impact on STD 
services. 
The impact in non-Medicaid expansion states is unclear.  The number of persons who obtained 
insurance through non-Medicaid providers is unknown at this time.  Moreover, persons who 
obtained insurance might not be current STD patients in public health clinics. Public health is 
not always aware of or involved in changes related to insurance expansion.  Insurance 
coverage might not lead to changes in care sites.  Assumptions about impact might be incorrect. 
Resource-related issues due to SHD/LHD budget cuts were identified.  An NCSD study reported 
that severe budget cuts to STD programs would affect the national public health infrastructure.  
SHD/LHD budget cuts also had implications beyond STD Programs, such as Title X, Women’s 
Health and Family Planning Programs that provide STD screening.  Budget cuts might reduce 
services and flexibility, while other issues might absorb limited resources that are needed for 
planning purposes to address future changes.  Issues that appear to be unrelated might lead to 
reduced funding for STDs. 
Wide variation was noted in the availability of primary care sites.  In some cases, locations of 
FQHCs did not match geographic areas of the country with the highest STD burden.  
Geographic disparities are important because decisions on integration could be made based on 
the inaccurate assumption that primary care options are widely available for STD patients.  
Inequitable access to primary care could leave segments of the population without options 
because unlike CHCs, not all PCPs offer comprehensive care. 
STD-related stigma and discrimination among state and local providers were noted.  For some 
populations (e.g., teens) and in some geographic areas (e.g., small towns and rural areas), 
persons might avoid primary care settings or other settings that require an insurance card due 
to the persistent stigma of STDs. 
Patients who fear discrimination based on race/ethnicity, poverty, sexual orientation or other 
factors might conclude that public health-run STD clinics are the only safe, supportive and 
comfortable clinical provider site due to their commitment to anonymity and confidentiality. The 
same populations that fear stigma and discrimination have an elevated risk for STDs and HIV, 
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but might avoid care.  Moreover, these populations might be less likely to be insured even in an 
ACA environment. 
Because state and local STD services are often linked to and housed with other services, 
including family planning, immunization and WIC services, the loss of STD services due to 
integration into primary care could result in an unintended consequence of adversely impacting 
the ability of the clinic to provide other services. 
The need for clinical expertise was emphasized.  Concerns were raised that primary care 
practices may not have sufficient expertise to treat complex STD-related cases. Initial skill-
building is needed for clinicians in training, while advanced clinical skills are needed for 
practicing physicians.  Public health STD expertise needs to be retained for referrals. 
Key integration needs and next steps were highlighted.  Information and TA are needed in 
establishing reimbursement systems, changing policies on explanation of benefits, and using 
health information technology.  Best practices need to be identified based on experiences and 
lessons learned from SHDs/LHDs that have successfully integrated services in the field.  TA is 
needed in piloting new integration models.  A continuum with 6 levels of integration for STD 
services (e.g., isolation, mutual awareness, cooperation, collaboration, partnership and full 
merger) may be helpful for SHDs/LHDs in determining their progress in integration. 
Kathy McNamara, RN 
Assistant Director of Clinical Affairs 
National Association of Community Health Centers 
Ms. McNamara described ongoing efforts in the field to reframe public health and primary care 
integration.  The mission of NACHC is to promote the provision of high-quality, comprehensive 
and affordable health care that is coordinated, culturally competent and community-directed for 
all medically underserved persons.  The 9,500 Health Centers collectively serve 23 million 
patients annually. 
The National Health Center Quality movement has tremendously evolved from a focus on 
accountability and quality control in the 1980s to the requirement for all CHCs to become 
recognized PCMHs by 2016.  The components to achieve population-based health must be 
strategic, structural, cultural and technical.  Emphasis is now being placed on developing and 
testing cost measures. 
Of the entire Health Center budget, Medicaid accounts for 38% and BPHC accounts for 16%.  
HRSA’s 2012 UDS data showed much larger numbers of Health Center patient visits than 
numbers of patients.  The numbers of patient visits were 571,696 for symptomatic and 
asymptomatic HIV, 18,480 for TB, 143,146 for syphilis and other STDs, 48,080 for HBV, and 
303,713 for HCV.  The numbers of patients were 114,881 for symptomatic and asymptomatic 
HIV, 9,755 for TB, 95,500 for syphilis and other STDs, 21,890 for HBV, and 132,078 for HCV. 
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NACHC’s position is that health reform should emphasize transformation of both primary care 
and public health by managing population health over time and across all settings, strongly 
focusing on performance measure and improvement, documenting costs, and generating 
improved savings and quality.  NACHC aims to strengthen the patient- and community-centered 
primary care health home through public health, community and primary care collaboration.  
These efforts are designed to maximize impact and avoid duplicity. 
The health home and transformation framework is built on population health and a reduction of 
disparities; patient, family and community engagement; and high value based on superior cost 
and quality outcomes.  To change systems of care, health funders are accountable to the four 
guiding principles of the Safety Net Medical Home Initiative:  establish the foundation, build 
relationships, change care delivery and reduce barriers to care. 
At this time, ~47% of Health Centers have achieved PCMH recognition by a national accrediting 
body and 37 and 106 Quality Improvement Coaches are National Committee for Quality 
Assurance PCMH Certified Content Experts.  Integrated Health Center Teams are now matched 
to their target populations, including Enhanced PCMH Teams, Mental Health High Intensity 
Teams, Intensive Outpatient Clinics, and Children with Special Health Needs Clinics. 
PCMHs provide clinical support to Expanded Care Teams based on the complexities of 
patients:  Examples of expanded teams include: 23 navigators to support tiers 3 and 4 patients 
for care management; 3 pediatric nurses to support tiers 3 and 4 children for care management; 
3 clinical pharmacists to support tiers 3 and 4 adults for medical management and transition; 
and 5 behavioral health consultants for behavioral health integrated care.  Community Health 
Teams inside Health Centers include nurse coordinators, social workers, nutrition specialists, 
community health workers, Medicaid care coordinators and public health specialists. 
NACHC convened an expert consultation to obtain input on developing its 2014-2015 
framework.  The advisory group described the components that should be included in NACHC’s 
framework for clinical/service integration and education:  a solid infrastructure, learning 
opportunities, measures, analytics and business outcomes. 
NACHC is applying its integration and education framework to implement innovation models.  
The “clinical decision support” intervention is focusing on chlamydia to align QI and information 
technology to specific measures at the patient level.  The “partnership” intervention is focusing 
on HIV in collaboration with non-Ryan White Health Centers, Ryan White Programs and PCAs.  
The “community partnership” intervention is focusing on chlamydia as a prototype for rapid QI of 
STDs. 
Lynda Meade, MPA 
Director of Clinical Services 
Michigan Primary Care Association 
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Ms. Meade described Michigan’s experience with integration in the cities of Detroit and Benton 
Harbor.  The mission of Michigan PCA is to promote, support and develop comprehensive, 
accessible and affordable community-based healthcare services to all Michigan residents.  
Michigan PCA closely collaborates with Health Centers on advocacy, policy, clinical support and 
other issues.  Across the state, 39 Health Centers provide care to >600,000 residents at >230 
delivery sites. 
Michigan built its foundation of integration with Health Centers, public health, Michigan PCA, 
Michigan Quality Improvement Network and community partners.  Michigan PCA also conducts 
activities in close collaboration with formal and informal advisory groups that have diverse, 
knowledgeable and trusted members who are committed to service and increased access.  
These components have been instrumental in addressing high HIV rates in Benton Harbor and 
extremely high rates of chlamydia in Detroit among young persons <30 years of age:  37% in 
the 15-19 age group, 40% in the 20-24 age group, and 11% in the 25-29 age group. 
Michigan’s state and local partners include Health Centers, ASOs, SHD/LHDs, a once-weekly 
community infectious disease clinic sponsored by a hospital, PLWH/AIDS, Michigan PCA and 
AETCs.  Michigan PCA will soon implement a rapid-cycle model for outbreak management of 
STDs.  In the project, 75% of sexually active women 15-25 years of age will be screened.  
Evidence-based treatment will be provided to at least 95% of women with positive test results.  
A new relationship will be built with a community that has served this population.  Partnerships 
will be created and sustained over time with the public health infrastructure. 
Activities to change the package aggregation will be completed in 3 weeks:  compile evidence-
based guidelines and protocols, confirm measures, convene expert faculty and partners, and 
develop the change package.  Validation will be completed in 1 week.  The “ramp-up” phase will 
be completed in 8 weeks:  provide education to Health Centers, implement reporting, convene 
weekly calls in weeks 1-2 and transition to biweekly calls thereafter, and conduct aggressive 
outreach.  The accelerated action period will be completed in 12 weeks:  convene weekly calls 
to all teams, engage faculty and hold open calls with external stakeholders.  A shared web-
based reporting system will be used to distribute sample policies, describe measures and 
regularly report key outcomes before, during and after the project. 
A partnership with Michigan PCA is beneficial due to its shared mission as well as diverse 
experiences and perspectives of staff.  Moreover, Health Centers are progressive and serve the 
same populations as public health.  Efforts must be targeted to populations in most need in 
order to change the health status and rates.  Based on Michigan PCA’s experience, five 
important concepts should be applied to inform integration efforts: 
• Identify common goals and create a vision of the meaning of “success” to clients and 
partners 
• Allow local partners to resolve issues and process improvement 
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• Value and consider all perspectives and needs 
• Consider sustainability and financing at the outset 
• Prepare for change and new strategies to provide services and address needs in 
PCMHs  
CHAC applauded the panel for their exciting activities and tremendous efforts to advance public 
health/primary care integration in the field.  The following topics were raised during the 
discussion. 
• The decision-making process for Health Centers to undertake and prioritize new 
responsibilities, such as primary care integration, with no additional resources. 
• The ability of the Safety Net Medical Home Initiative to address barriers to care in the 
hard-to-reach populations of migrants and homeless persons. 
• Efforts to adapt and incorporate integrated public health surveillance systems and 
measures into Health Centers. 
• The need to increase the use of community health workers in integration efforts due to 
their demonstrated success in reducing stigma related to HIV and STD testing. 
Update by the CHAC Ryan White Reauthorization Workgroup 
Kathleen Clanon, MD 
Director, Division of HIV Services 
Alameda County Medical Center 
CHAC Member & Workgroup Chair 
Dr. Clanon covered the following topics in her update on the workgroup’s recent activities.  The 
workgroup’s original charge in May 2012 was to develop and present recommendations to 
CHAC regarding reauthorization of RWHAP that would reflect the evolving care needs in the 
context of ACA implementation.  Despite the expiration of its authorizing statute in September 
2013, HRSA is implementing the RWHAP through continued appropriation for the program.  No 
definite plans have been announced for RWHAP reauthorization at this time. 
The workgroup convened a teleconference meeting in December 2013 and is now soliciting 
CHAC’s input in two areas.  First, the workgroup’s current charge should be suspended until 
clear plans are announced that actions will be taken on RWHAP reauthorization.  Second, 
consideration should be given to charging the workgroup with new tasks: 
• Advise CDC and HRSA on the contribution of RWHAP to progress on the National 
HIV/AIDS Strategy, particularly goal 4 that emphasizes the need for collaboration among 
federal agencies 
 
Meeting Minutes: CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment 
May 21-22, 2014 ♦ Page 57 
 
• Advise HRSA on RWHAP’s progress in meeting basic ACA goals (e.g., uninterrupted 
access to insurance, care and medications for low-income PLWH) 
• Advise HRSA on the best use of RWHAP as part of the national investment in achieving 
the goal of “zero new cases” 
In response to the workgroup’s request for input, Dr. Cheever proposed two areas that would be 
particularly helpful for HRSA to obtain external advice and guidance on RWHAP.  First, 
programmatic areas in RWHAP that need to be modified to respond to changes in the health 
environment as a result of ACA should be regularly monitored and evaluated.  Second, input 
should be provided on RWHAP data that HRSA should routinely gather and analyze to inform 
reauthorization in the future.  Because reauthorization is not planned at this time, Dr. Cheever 
also advised the workgroup to change its name to reflect broader RWHAP issues beyond 
reauthorization. 
CHAC also responded to the workgroup’s request for input.  The members emphasized the 
need to maintain the workgroup, but with a more focused charge that would be more responsive 
to the needs of CDC and HRSA.  Prevention, care and treatment resources that are allocated 
by CDC and HRSA are instrumental in sustaining the healthcare infrastructure, particularly as 
efforts are now being made to enhance public health/primary care integration.  CHAC should 
continue to provide CDC and HRSA with evidence-based policy guidance. 
Based on this feedback, Dr. Clanon announced that the next steps would be for the newly 
expanded “Ryan White Workgroup” to focus on the tasks proposed by Dr. Cheever and the 
CHAC members.  The workgroup would refine its charge based on these tasks and present an 
update at the next CHAC meeting. 
CHAC Business Session 
Jeanne Marrazzo, MD, MPH, CHAC co-Chair 
Professor of Medicine, Harborview Medical Center 
University of Washington 
Dr. Marrazzo opened the business session and called for CHAC’s review, discussion and/or 
formal action on the following topics.1
 
Topic 1: Draft CHAC Meeting Minutes 
 
                                                          
1Editor’s Note: The minutes reflect the recommendations/resolutions that CHAC revised and finalized 
immediately after the May 2014 meeting, but formally approved as drafts during the meeting. 
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A motion was properly placed on the floor by Dr. Jeanne Marrazzo and seconded by Mr. Kali 
Lindsey for CHAC to approve the previous meeting minutes. 
CHAC unanimously adopted the Draft November 13-14, 2013 Meeting Minutes with no 
changes or further discussion. 
 
Topic 2:  National HCV Program 
 
Dr. Marrazzo presented the National HCV Program recommendation for CHAC’s consideration, 
deliberation and formal action. 
As summarized in the HHS National Viral Hepatitis Action Plan (VHAP), the hepatitis C 
virus (HCV) epidemic is causing increased morbidity and mortality in the United States, 
including an alarming trend in new HCV infections in young persons who inject drugs.  
New treatments offer the hope of controlling the epidemic and saving hundreds of 
thousands of lives.  Lessons learned from the successful Ryan White Program will be 
invaluable as the nation develops a response to the HCV epidemic and should serve as a 
model to maximize access to care and treatment services. 
Current resource levels invested in the viral hepatitis response are insufficient to combat 
the challenge of HCV and to carry out VHAP.  Until such funding is identified, HRSA and 
CDC (acting within the constraints of existing statutes) should collaborate and leverage 
existing HIV and STD resources to develop a national program for awareness, screening, 
surveillance, linkage to care and cure of HCV.  Therefore: 
• CHAC recommends that CDC commission or request an independent assessment of 
cost issues that currently limit access to HCV treatment, with specific attention to 
target reductions in cost of newer agents. 
• Because some state laws require HIV screening as part of some healthcare activities 
and some have extended this to HCV, CHAC recommends that CDC share "best 
practices" in this area of public health policy in order to strengthen momentum for 
expanded screening. 
• CHAC recommends that CDC and HRSA conduct a legislative review to determine 
what additional HCV activities can be performed by CDC and HRSA under existing 
statutes. 
• CHAC recommends that new programmatic guidance be developed to give to 
Federally Qualified Health Centers and Ryan White grantees regarding HCV 
screening, care and treatment for persons with HCV and HIV/HCV co-infection. 
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• CHAC recommends that data regarding performance on HCV screening and linkage 
to treatment be prioritized for collection, analysis and feedback to funded programs 
and for project officer discussions with grantees. 
• CHAC recommends the development of standardized performance measures and 
data elements for HCV surveillance and corresponding funding support for 
epidemiologic capacity at the state health department level. 
 
 
Co-Chair’s call for a vote Motion properly made by Dr. Sanjeev Arora for CHAC to 
adopt the National HCV Program recommendation 
Motion seconded by Mr. Guillermo Chacon 
Outcome of vote Motion unanimously passed by 13 CHAC voting 
members 
Next steps Dr. Marrazzo will convey CHAC’s formal recommendation in 
a letter to the HHS Secretary, CDC Director and HRSA 
Administrator. 
 
 
 
Topic 3:  HIV and HCV Testing 
 
Dr. Johnson presented the HIV/HCV Testing resolution for CHAC’s consideration, deliberation 
and formal action. 
Testing for HIV and HCV is routinely recommended in adults, including by CDC and the 
U.S. Preventive Services Task Force.  However, currently 1 in 6 HIV-infected persons 
and 1 in 2 HCV-infected persons are unaware of their diagnosis. 
CHAC recommends that CDC and HRSA work to enhance adherence to these testing 
guidelines through their work with their directly-funded clinical programs and through 
collaborations with other federal agencies, such as the Centers for Medicare and 
Medicaid Services.  Incorporation of routine HIV and HCV testing into Meaningful Use 
requirements, core quality measures, reminders in electronic health records, and pay-for-
performance programs may enhance provider adherence to these guidelines and 
increase the proportion of patients living with these infections who are diagnosed and 
linked to care. 
Co-Chair’s call for a vote Motion properly made by Dr. Steven Johnson for CHAC to 
adopt the HIV and HCV testing resolution 
Motion seconded by Dr. Sanjeev Arora 
Outcome of vote Motion unanimously passed by 13 CHAC voting 
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members 
Next steps Dr. Marrazzo will convey CHAC’s formal resolution in a 
letter to the CDC Director and HRSA Administrator. 
 
Topic 4:  Adolescent Health 
 
Dr. Clanon presented the Adolescent Health recommendation for CHAC’s consideration, 
deliberation and formal action. 
CHAC endorses the CDC Division of Adolescent and School Health’s (DASH) list of 
sexual health services for youth as reasonable with proven effectiveness. 
CHAC recommends that CDC issue formal guidelines for these services to be provided 
by school nurses or in School-Based Health Clinics for all youth, including LGBT youth 
and young men who have sex with men.  The DASH list of sexual health services for 
youth includes: 
1. HIV counseling and testing 
2. STD testing and treatment 
3. Pregnancy testing 
4. Provision of condoms 
5. Provision of contraception other than condoms (e.g., birth control pill and long-
acting reversible contraception) 
6. Prenatal care 
7. Human papillomavirus vaccine administration 
In instances where these services cannot be accessed or administered by a school nurse 
or at a School-Based Health Clinic, referrals should be made to an established teen-
friendly health clinic in the community. 
Co-Chair’s Call for a vote Motion properly made by Mr. Guillermo Chacon for CHAC to 
adopt the adolescent health recommendation 
Motion seconded by Dr. Bruce Agins 
Outcome of vote Motion unanimously passed by 13 CHAC voting 
members 
Next steps Dr. Marrazzo will convey CHAC’s formal resolution in a 
letter to the CDC Director. 
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Topic 5:  PrEP Implementation 
 
Dr. Marrazzo presented the PrEP Implementation resolution for CHAC’s consideration, 
deliberation and formal action. 
CHAC congratulates CDC on the recent release of the Preexposure Prophylaxis (PrEP) 
for the Prevention of HIV Infection in the United States-2014 Guidelines. While PrEP 
represents a promising new addition to the HIV prevention toolkit, uptake of PrEP 
utilization at a national level remains low. 
CHAC recommends that CDC provide periodic updates on key implementation metrics, 
including data derived from ongoing demonstration projects, to inform its approach and 
consideration of the following activities and related recommendations: 
• Methods to target and deliver PrEP to individuals and populations in urgent need 
• Methods to enhance access to PrEP (including delivery in HIV care clinics, 
primary care settings, and capacity-building and clinical training support efforts for 
prescribers) 
• Methods to measure and address cost and health insurance coverage concerns, 
including cost-sharing obligations that may present a barrier to receipt of PrEP 
• Methods to measure the impact of PrEP on the incidence of sexually-transmitted 
diseases (STDs) other than HIV and changes in sexual and drug-injection 
behaviors that may increase risks for HIV/STD and viral hepatitis exposure or 
infection. 
Co-Chair’s Call for a vote Motion properly made by Dr. Marjorie Hill for CHAC to adopt 
the PrEP implementation resolution 
Motion seconded by Mr. Kali Lindsey 
Outcome of vote Motion unanimously passed by 13 CHAC voting 
members 
Next steps Dr. Marrazzo will convey CHAC’s formal resolution in a 
letter to the CDC Director. 
 
Topic 6:  Prescription Drug Overdose Epidemic 
 
Dr. Marrazzo presented the Prescription Drug Overdose Epidemic resolution for CHAC’s 
consideration, deliberation and formal action. 
 
Meeting Minutes: CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment 
May 21-22, 2014 ♦ Page 62 
 
CHAC is concerned about the alarming epidemic of opioid overdoses in the United 
States. 
Considering the alarming increases in deaths associated with overdoses of prescription 
opioid analgesics and heroin; 
Considering the risks to those prescribed opioids with concomitant use of other licit or 
illicit drugs or alcohol that may result in overdose related to drug-drug interactions;  
Considering the social and behavioral connections between opioid use and injection, and 
risk for exposure to or acquisition of HIV, sexually-transmitted diseases and viral 
hepatitis; 
Considering those risks, morbidity and mortality could be reduced by making education 
and training on the signs and symptoms of opioid overdose and use of naloxone widely 
available through federal guidance to states and communities and by increasing access 
to treatment for opioid use disorders, including the use of pharmacotherapies that are 
FDA-approved in combination with psychosocial therapies; 
Considering these treatment options for opioid use disorders can be available in primary 
care settings or in specialized substance abuse treatment programs underscoring the 
need for training of providers to increase the delivery of these services to those in need; 
Be it resolved that CHAC calls for proactive program initiatives in response to the opioid 
overdose epidemic to avoid more deaths or potential exposure to hepatitis B, hepatitis C, 
or HIV in vulnerable individuals and populations across the United States and U.S. 
territories. 
CHAC calls for improvements to patient safety through person-centered and holistic care 
to better address drug user health needs, access to medical care, communicable disease 
screening and treatment, and substance abuse treatment services, and to improve their 
well-being. 
CHAC calls on all federal agencies working in this area to increase collaboration to 
improve integrated health services for drug users in the nation. 
Co-Chair’s Call for a vote Motion properly made by Dr. Jeanne Marrazzo for CHAC to 
adopt the prescription drug overdose epidemic resolution 
Motion seconded by Dr. Britt Rios-Ellis 
Outcome of vote Motion unanimously passed by 13 CHAC voting 
members 
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Next steps Dr. Marrazzo will convey CHAC’s formal resolution in a 
letter to the HHS Secretary, CDC Director and HRSA 
Administrator. 
 
 
 
Topic 7:  STD Prevention Among MSM 
 
Dr. Marrazzo presented the STD Prevention Among MSM resolution for CHAC’s consideration, 
deliberation and formal action. 
CHAC is concerned about the sustained increase in bacterial STDs among MSM.  CHAC 
recommends that efforts to enhance the detection and treatment of these infections, 
including support for extragenital testing for chlamydia and gonorrhea, be prioritized. 
Co-Chair’s Call for a vote Motion properly made by Mr. Guillermo Chacon for CHAC to 
adopt the STD prevention among MSM resolution 
Motion seconded by Ms. Angelique Croasdale 
Outcome of vote Motion unanimously passed by 13 CHAC voting 
members 
Next steps Dr. Marrazzo will convey CHAC’s formal resolution in a 
letter to the CDC Director. 
 
Topic 8: New Agenda Items 
 
Dr. Marrazzo moderated CHAC’s discussion, review and summary of new agenda items that 
were raised over the course of the meeting. 
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NEW AGENDA ITEMS 
 
 
Presenter(s) 
 
Topic 
 
CMS/CCIIO Overview of HIV-relevant services covered under ACA, e.g.: 
• Screening and outreach 
• Provision of specific ARV drugs 
• Coverage of PrEP 
• ACA performance measures to reduce health disparities 
• Efforts by private Health Insurance Exchanges to address the 
unintended consequence of higher co-pays for HIV medications 
HRSA Update on ACA-related issues: 
• Integration efforts in an ACA environment 
• ACA-related problems reported to date by RWHAP grantees that 
are affecting HIV care 
HRSA Overview of the Ryan White HIV Workforce Study 
CDC, HRSA & CMS Extensive update on HCV screening and treatment: 
• CDC/HRSA:  Overview of an interagency, collaborative plan to 
implement the six VHAP activities the HHS Secretary prioritized for 
2014-2016 
• CDC/HRSA:  Overview of existing resources and new opportunities 
for HCV screening and treatment, particularly with the availability of 
new drugs 
• CDC: 
o New studies and activities that specifically will be targeted to the 
new high-risk HCV population (e.g., young, white persons 18-29 
years of age in suburban areas with a history of prescription drug 
use) 
o Efforts to redesign existing data systems to better characterize 
and monitor the epidemiology and treatment outcomes of the 
high-risk HCV population and deliver effective harm-reduction 
interventions (e.g., syringe exchange and drug treatment 
programs) 
o DVH’s progress on including new variables in NHBS to capture 
data on MSM, non-IDUs and other populations at high risk for 
HCV 
• HRSA:  Progress on requesting all FQHCs to incorporate an 
electronic reminder into EHRs to conduct HCV screening of the 
1945-1965 birth cohort 
• CMS:  HCV performance measures and cost estimates to establish 
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NEW AGENDA ITEMS 
 
 
 
Presenter(s) 
 
Topic 
 
a new National Hepatitis C Program, including the lowest cost of 
drugs that would achieve the greatest public health impact 
CDC & HRSA Overview of ongoing tele-medicine projects that support expanded 
outreach and improvement in HIV, HCV and STD prevention and care 
CDC & SAMHSA Update on drug user health after additional substance use data are 
presented during an upcoming summit 
CDC & Guest 
Speakers 
Overview of both anecdotal and evidence-based PrEP experiences in 
the field, particularly PrEP prescriptions and insurance coverage for 
high-risk groups: 
• Results of the New York State PrEP project that is being piloted at 
six sites and targeted to diverse populations, including LGBT, 
Asians/Pacific Islanders, African Americans and adolescents 
 
 
 
Topic 9: Action Items 
 
Dr. Marrazzo led CHAC in a review of the action items that were raised over the course of the 
meeting. 
 
NEW ACTION ITEMS 
 
 
Responsibility 
 
Action Step 
 
CDC (John Ward) Distribute information and links to CHAC on the “National Summit to 
Improve Access to HCV Testing, Treatment and Cure” webcast that 
CDC will host on June 17-18, 2014 
CHAC (Bruce Agins) Identify a guest speaker to report the results of the New York State 
PrEP pilot project 
CHAC (Bruce Agins & 
Kali Lindsey) 
Draft a resolution on integration, as the Integration Workgroup co-
Chairs, for CHAC’s consideration, deliberation and formal action 
during the next meeting 
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NEW ACTION ITEMS 
 
 
Responsibility 
 
Action Step 
 
CHAC co-Chair Reestablish the Viral Hepatitis Workgroup with new members: 
• Dr. Sanjeev Arora (Chair) 
• Mr. Guillermo Chacon 
• Dr. Britt Rios-Ellis 
CHAC co-Chair & 
DFOs 
Distribute an e-mail to confirm the membership of the Data 
Workgroup, in addition to Dr. Jennifer Kates 
HRSA 
(Kristen Mangold) 
Participate on the first teleconference of the reestablished Viral 
Hepatitis Workgroup and present the parts of the RWHAP legislation 
that pertain to HCV 
CHAC Members Ongoing discussion to revisit whether the Sexual Health Workgroup 
should be reestablished 
Closing Session 
Dr. Marrazzo thanked the CHAC members for their continued commitment and dedication to 
improve HIV, viral hepatitis and STD prevention and treatment for the nation.  She noted that 
the informative presentations by CDC, HRSA and the guest speakers resulted in an extremely 
productive meeting.  Drs. Mermin and Cheever also thanked the CHAC members for providing 
tremendously helpful advice to guide the CDC and HRSA prevention and treatment programs. 
The next CHAC meeting would be HRSA-focused and virtually convened on November 19-20, 
2014.  With no further discussion or business brought before CHAC, Dr. Marrazzo adjourned 
the meeting at 12:54 p.m. on May 22, 2014. 
       I hereby certify that to the best of my 
knowledge, the foregoing Minutes of the 
proceedings are accurate and complete. 
___________________    ___________________________________ 
Date       Jeanne Marrazzo, MD, MPH, Co-Chair 
       CDC/HRSA Advisory Committee on HIV, 
       Viral Hepatitis and STD Prevention and 
       Treatment 
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Glossary of Acronyms 
AASLD American Association for the Study of Liver Diseases 
ACA Affordable Care Act 
ACE Affordable Care Enrollment 
ACO Accountable Care Organization 
AETCs AIDS Education and Training Centers 
AHRQ Agency for Healthcare Research and Quality 
AMD Advanced Molecular Detection 
ANAC Association of Nurses in AIDS Care 
ART Antiretroviral Therapy 
ARV Antiretroviral 
ASOs AIDS Service Organizations 
ASTHO Association of State and Territorial Health Officials 
BMSM Black Men Who Have Sex With Men 
BPHC Bureau of Primary Health Care 
CBOs Community-Based Organizations 
CCIIO Center for Consumer Information and Insurance Oversight 
CDC Centers for Disease Control and Prevention 
CHAC CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and 
STD Prevention and Treatment 
CHCs Community Health Centers 
CMS Centers for Medicare and Medicaid Services 
CoAg Cooperative Agreement 
DASH Division of Adolescent and School Health  
DFOs Designated Federal Officers 
DHAP Division of HIV/AIDS Prevention  
DIS Disease Investigation Services 
DSTDP Division of STD Prevention 
DVH Division of Viral Hepatitis 
EBIs Evidence-Based Interventions 
EHRs Electronic Health Records 
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FDA U.S. Food and Drug Administration 
FOA Funding Opportunity Announcement 
FPL Federal Poverty Level 
FQHCs Federally Qualified Health Centers 
HAB HIV/AIDS Bureau 
HBV Hepatitis B Virus 
HCV Hepatitis C Virus  
HHS U.S. Department of Health and Human Services 
HRSA Health Resources and Services Administration 
IDSA Infectious Diseases Society of America 
IDU; IDUs Injection Drug Use; Injection Drug Users 
IOM Institute of Medicine 
KFF Kaiser Family Foundation 
LEAs Local Education Agencies 
LGBT Lesbian/Gay/Bisexual/Transgender 
LHDs Local Health Departments 
MAI Minority AIDS Initiative 
MMP Medical Monitoring Project 
MMWR Morbidity and Mortality Weekly Report 
MSM Men Who Have Sex With Men  
NACHC National Association of Community Health Centers 
NASTAD National Alliance of State and Territorial AIDS Directors 
NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention  
NCSD National Coalition of STD Directors 
NHBS National HIV Behavioral Surveillance System 
NIH National Institutes of Health 
OAMC Outpatient Ambulatory Medical Care 
OPTN Organ Procurement and Transplantation Network 
PACHA Presidential Advisory Council on HIV/AIDS 
PCAs Primary Care Associations 
PCMH Patient-Centered Medical Home 
PCPs Primary Care Providers 
PCSI Program Collaboration and Service Integration 
PLWH Persons Living with HIV 
POA Prescription Opioid Analgesic 
PrEP Pre-Exposure Prophylaxis 
Project ECHO® Extension for Community Healthcare Outcomes 
PWID Persons Who Inject Drugs 
PwP Prevention with Positives 
QI Quality Improvement 
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RWHAP Ryan White HIV/AIDS Program 
SAMHSA Substance Abuse and Mental Health Service Administration  
SBHCs School-Based Health Clinics 
SEAs State Education Agencies 
SFDPH San Francisco Department of Public Health 
SHDs State Health Departments 
SHIPP Sustainable Health Center Implementation PrEP Pilot 
SHPPS School Health Policies and Practices Study 
SPNS Special Projects of National Significance  
STDs Sexually-Transmitted Diseases 
SVR Sustained Virologic Response 
TA Technical Assistance 
TAI The AIDS Institute 
TasP Treatment as Prevention 
TB Tuberculosis 
TDF/FTC Tenofir Disoproxil Fumarate/Emtricitabine 
The Institute Institute on Urban Health Research and Practice 
UDS Uniform Data System 
USPSTF U.S. Preventive Services Task Force 
VHAP Viral Hepatitis Action Plan 
WIC Women, Infants and Children 
YMSM Young Men Who Have Sex With Men 
YRBS Youth Risk Behavior Surveillance System 
